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Immune Cell Potentiating Factor (ICPF) represents a class of biological response
modifiers initially only found within active caprine serum fractions. Controlled studies
have since demonstrated active ICPF derived from several non-caprine mammalian
sources; including equine and human. ICPF is able to increase survivability in murine
gram negative induced sepsis (60%) as well as secondary infection and subsequent sepsis
in canines infected within canine parvo virus 2 (36%) despite showing no innate antiviral
properties. ICPF is able to initiate systemic proteomic changes within several organ
systems; including serum, liver, brain, lung, and spleen. ICPF initiated an early acute
phase response, specifically through the increased expression of serum amyloid A, with
systemic serum levels increasing from 1.5 µg/mL to 403.0 µg/mL within 24 hours and
increased to 3,400 µg/mL within 48 hours following ICPF administration. Evaluation of
cytokine expression following ICPF treatment revealed the up-regulation of IL-6, INF-γ,
and the chemokine CXCL1\KC in vivo as well as the expression of IL-6 and IFN-γ in
vitro within 3 hours of treatment. Development of an in vitro bioassay through the
expression of IL-6 and IFN-γ within whole blood and peripheral blood mononuclear cells
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will allow for further elucidation and testing of ICPF outside of an animal host. The
early expression of proinflammatory cytokines and chemokines, an acute phase response
including serum amyloid A, and ICPF’s inability to alleviate mortality in a
lipopolysaccharide animal mortality model strongly indicates an active role for ICPF as
an immune regulatory peptide capable of promoting an early inflammatory response to
Salmonella enterica serovar Typhimurium thereby reducing the risk and mortality
associated with sepsis.
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CHAPTER I
LITERATURE REVIEW
Biological Response Modifiers (BRMs) represent a relatively new and untapped
class of therapeutic compounds which play a fundamental role in the emerging field of
immunotherapy. Traditional therapeutic approaches within the pharmaceutical industry
and academia have resulted in specific medicines to serve as treatments to many human
and veterinary ailments, but now, with an ever increasing understanding of the
complexities and power of the mammalian and avian immune systems, we are closer than
ever to being able to modulate subtle attributes of the immune system to abate many
pathologies.
While the earliest forms of immunotherapy can be traced back over 70 years to
the use of immunoglobulins for the treatment of pneumococcal infections (Donta 2002),
it was not until recently that our understanding of the immune system was sufficient to
begin truly harnessing its power. The main constituents of immunotherapy include
cytokines, chemokines, mono/polyclonal antibodies, immune modulating proteins and
peptides, immune stimulating endotoxins (lipids and carbohydrates), and synthetic
compounds capable of modulating subtle functions and cell types, such as directing Tcell maturation and phenotypes (Bruns, Meinken et al. 2009). With the advent and
successful implementation of interleukin and interferon immunotherapies in oncology,
attention and support has once again been redirected toward thwarting viral and bacterial
pathologies.
9

Immunotherapies are of particular interest because they proffer the ability to
directly harness the immense power of the immune system, as well as the ability to down
modulate an immune response, which if persistent can become detrimental - as is the case
with autoimmune deficiencies and sepsis. Instead of developing a drug to combat a
specific pathogen or symptom, immunotherapy promises to modulate our current immune
system so that it may better address and alleviate the pathology, thereby reducing or
eliminating a pathogen’s ability to circumvent treatment.
The mammalian immune system can be loosely separated into two distinct
entities; the innate and adaptive immune systems. The adaptive immune response is
critical to allow an organism to adapt and mount faster and more efficient immune
responses to pathogens it has encountered in the past and is therefore likely to encounter
again. The induction of an adaptive immune response to a previously un-encountered
pathogen is a time consuming process which is tightly regulated by both positive and
negative regulatory checkpoints to prevent detrimental autoimmunity. To protect an
organism from novel pathogens, the innate immune system is responsible for holding
pathogens in check, mounting a frontline defense, recruiting additional cell types,
processing pathogens, and presenting antigenic (immunogentic) proteins, lipids and
carbohydrates to the cells of the adaptive system.
The innate immune system utilizes two distinct strategies for the detection of
pathogens; recognition of missing self, and recognition of microbial non-self (Raulet
2006; Kawai and Akira 2009). Recognition of microbial non-self is usually
accomplished by a cell’s ability to recognize specific molecular patterns which are well
conserved and fundamentally important to the pathogen, yet are not produced or used by
the host. Dr. Charles Janeway first proposed and defended the theory that germline
10

encoded receptors (Janeway) were able to recognize and respond to common pathogen
motifs in the late 1980’s, a theory which has been shown to be accurate and initiated our
current understanding of innate immunology. These Pathogen Associated Molecular
Patterns (PAMPS) are recognized by Pattern Recognition Receptors (PRR) on cells,
primarily of the innate immune system. PRR are broken into three functional categories;
receptors which detect and signal the presence of microbial pathogens and initiate an
inflammatory response, soluble secreted PRR which assist in the activation of the
compliment immune cascade, opsonization, and serve as coreceptors for other membrane
bound PRR, and phagocytic PRR which initiate phagocytosis of the PAMP and possible
antigen processing (Medzhitov 2009).
Of particular importance in bridging the gap between adaptive and innate
immunity are the Toll-Like Receptors (TLR). These PRR are responsible for detection
and signaling for the presence of microbial pathogens and initiating a pro-inflammatory
response. PRR are able to recognize and respond to a wide variety of PAMPs such as
extracellular type 1 transmembrane, intracellular endosomal (Kuroishi, Tanaka et al.
2007), and recently discovered mammalian soluble cytosolic and secreted TLR (Rad,
Ballhorn et al. 2009). Cellular TLR location can often be reflective of its immunological
function (Table 1).
Toll-like receptors are able to recognize and bind vastly different PAMPS,
including nucleic acids, protein, lipo and glycoproteins, fatty acids, and carbohydrates.
These ligands are structurally diverse and unrelated, yet via a mechanism that is not yet
fully understood, TLR are able to recognize and bind them with remarkable fidelity.
TLRs are comprised of three domain regions, consisting of a leucine rich repeat region, a
trans-membrane region, and a Toll/IL-1R domain. The Toll/IL-1R domain is exposed
11

within the cytosol and interacts with adaptor proteins, resulting in the recruitment of IL1R associated kinases, and ultimately activation NF-κβ and associated proinflammatory
cytokines (Lasker and Nair 2006). An important characteristic of the TLR ligand
response is the use of accessory molecules such as myD88 and lipopolysaccharide
binding protein (Schnare, Barton et al. 2001) to further enhance and direct the immune
response (Lien, Means et al. 2000). Upon detection, PRR allow for a fast and powerful
(inflammatory) immune response which may include the activation of acute phase
proteins and compliment from hepatocytes, neutrophil recruitment and influx,
modification of cytokine and chemokine networks, changes in cellular morphology,
surface receptor profiles, localized immune cell populations, and physiological responses
such as pyrogenicity and vasodilation.
Although not perfect, the innate immune system wields awesome power, and even
short delays in one aspect of the innate immune response can lead to death from an
otherwise innocuous pathogenic infection (Yang, Dorner et al. 2002). Many autoimmune
diseases such as rheumatoid arthritis (Vander Cruyssen, Peene et al. 2005), multiple
sclerosis (Derfuss, Parikh et al. 2009), sepsis, and septic shock (Nasraway 2003) are the
result of poor or mis-regulation and control of the innate/inflammatory system.
Modulation of the innate immune system, specifically via TLR and the junction to
acquired immunity are of renewed interest for pharmaceutical companies in their
development of new immunotherapies. At the time of writing, TLR agonists and
antagonists are in development at ten major pharmaceutical companies, with intended
uses ranging from next generation vaccine adjuvants to modulators of viral, cancer, autoimmunity, and infectious diseases (Cook, Pisetsky et al. 2004; Hoffman, Smith et al.
2005).
12
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Ubiquitous
Plasmacytoid dendritic cells, B-cells
Myeloid dendritic cells
Human = Plasmacytoid dendritic cells,
B-cells : Mouse = Macrophages,
dendritic cells

TLR 6 (TLR 2 co-receptor)

TLR 7

TLR 8

ND
ND
ND

TLR 11 (human pseudogene)

TLR 12 (human pseudogene)

TLR 13 (human pseudogene)

Principle cellular subset, location, and ligands.
* Not determined

ND

TLR 10 (mouse pseudogene)

TLR 9
*

Macrophages, dendritic cells, epithelial

TLR 5

TLR 4

Macrophages, dendritic cells, epithelial
Macrophages, dendritic cells, epithelial,
neutrophils, mastocytes, B-cells,
endothelial, fibroblasts, muscle

ND

ND

ND

ND

Endosome/Lysosome

Intracellular

Intracellular

Plasma Membrane

Intracellular

Plasma Membrane

Intracellular

Plasma Membrane

Macrophages, dendritic cells, B-cells,
epithelial

TLR 2

TLR 3

Plasma Membrane

Ubiquitous

TLR 1 (TLR 2 co-receptor)

Cellular Location

Cell Subset

Human and mouse Toll Like Receptors

Human and Mouse

Table 1

ND

ND

ND
Uropathgenic bacteria,
Profilin-like molecule

Unmethylated CpG DNA

G-Rich Oligonucleotides

ssRNA

Flagellin
(Diacyl) Lipoproteins,
Lipoteichoic acid, zymosan

Lipopolysaccarides

dsRNA, poly (I:C)

Recognized PAMPS
(Triacyl) Lipoproteins,
Lipoteichoic acid, zymosan
Peptidoglycans,
glycoproteins, Lipoproteins,
Lipoteichoic acid, zymosan

(Medzhitov 2009)

(Medzhitov 2009)

(Medzhitov 2009)
(Lauw, Caffrey et al. 2005; Yarovinsky,
Hieny et al. 2008; Rad, Ballhorn et al. 2009)

(Venugopal, Nutman et al. 2009)

(Medzhitov 2009; Rad, Ballhorn et al. 2009)
(Lund, Alexopoulou et al. 2004; Venugopal,
Nutman et al. 2009)
(Gorden, Gorski et al. 2005; Venugopal,
Nutman et al. 2009)

(Rad, Ballhorn et al. 2009)
(Uematsu, Myoung Ho et al. 2006; Rad,
Ballhorn et al. 2009)

(Medzhitov 2009; Rad, Ballhorn et al. 2009;
Venugopal, Nutman et al. 2009)
(Alexopoulou, Holt et al. 2001; Venugopal,
Nutman et al. 2009)

Source (Lit.)
(Medzhitov 2009; Rad, Ballhorn et al. 2009;
Venugopal, Nutman et al. 2009)

Regulation and communication among various mechanisms of the innate immune
system is primarily accomplished through cytokine and chemokine signaling. Cytokines
are proteins or peptides secreted from cells which operate in either an autocrine or
paracrine fashion. The semantic distinction between cytokine, chemokine, hormone, and
growth factor is imprecise; but generally cytokines and chemokines operate in a localized
manner, have a short half life, and act locally on targeted leukocytes (Flajnik and
Pasquier 2009), however temporal, proximal, and cellular exceptions do exist. Cytokine
and chemokine nomenclature has also been problematic, with definitions and names
which change as more functional and structural information become available. Cytokines
and chemokines can be broadly broken into four families; type 1 and type II cytokines
and interferons, interleukin-1, TNF-type cytokines, and chemokines. Cytokines can have
a very broad range of effects on cells of the immune system; promoting cellular
differentiation of hematopoietic stem cells (Dao and Nolta 2007), chemotaxis (Horuk
2001), apoptosis (Ware 2003), immune cell (de)activation, and systemic proteomic shifts,
as seen in the acute phase response (Tissieres, Dunn-Siegrist et al. 2008). While many
cytokines are referred to as interleukins, stemming from the initial belief that they were
secreted by and targeted leukocytes, there are many interleukins which are released by
and target somatic cells outside of the traditional immune system.
Type 1 cytokines are a family which shares a conserved structural form consisting
of four α helixes in an ‘up-up-down-down’ topology and similar receptor homology.
Knowledge that a cytokine is a member of the type 1 family of cytokines does not
indicate function, but does present structural and mechanistic signal transduction
information (Leonard 2009). Type II cytokines are primarily composed of interferons
(IFNs) and the interleukin-10 family of cytokines which include IL-19, IL-20, IL-22, IL14

24, IL-26, IL-28, and IL-29. IFNs are further separated into type I IFNs consisting of
IFN-α, β, ε, κ, ω, δ, τ all encoded from genes clustered on human chromosome 9, while
the type II IFN is IFN-γ, encoded from human chromosome 12 (Honda, Takaoka et al.
2006). While IFNs are sometimes referenced of as a separate group from IL-10, they
both bind to type II cytokine receptors, show strong structural homology (Zdanov 2004)
and are therefore also referred to as type II cytokines.
The interleukin-1 family consists of 11 cytokines, of which four are well
characterized, IL-1α, IL-1β, IL-1 receptor agonist, and IL-18. Members of the IL-1
family primarily affect the inflammatory response and are highly pleiotropic, initiating
both pro and anti inflammatory cascades. The IL-1β cytokine has been shown to
promote gene expression and synthesis of type 2 phospholipase A (Ashraf, Murakami et
al. 1996), COX-2 (Duggan, Lindstrom et al. 2007; Ohama, Hori et al. 2007), and nitric
oxide synthase (Ohama, Hori et al. 2007). Regulation of the IL-1 family via receptor
agonists and monoclonal antibodies has been shown to be effective in modulating
inflammatory processes associated with inflammatory based autoimmune diseases such
as rheumatoid arthritis (Horai, Saijo et al. 2000; Economides, Carpenter et al. 2003), and
type 2 diabetes (Larsen, Faulenbach et al. 2007).
The Tissue Necrosis Factor (TNF) family of cytokines is by far one of the largest,
most diverse and intricate cytokine networks. Many functions of TNF lay outside the
purview of immunology, these cytokines are nevertheless important for a host of immune
responses. The main function of TNF on many immune cells is the activation of
transcription factors NF-κB and/or AP-1. NF-κB is of particular importance as it
functions to regulate nuclear transcription in nearly all cells undergoing an
immunological response from pathogens, formation of secondary lymphoid organ
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structures (Siebenlist, Brown et al. 2005) and has more recently been associated with Bcell isotype switching, T and B cell development, and cytokine production (Li and Verma
2002). The ability of the TNF family of cytokines to regulate and control so many
diverse functions within the immune system is accomplished, in part, by an evolutionarily
ancient and intricate network of associated proteins, soluble and membrane bound
cognate receptor molecules, and downstream cell signaling checkpoints and
modifications (Li and Verma 2002; Siebenlist, Brown et al. 2005). The large assortment
of cross utilization of TNF and associated receptors was initially believed to be a built in
redundancy (Kuprash, Alimzhanov et al. 2002), but are now viewed as complete systems
with associated functions (Pfeffer 2003). Sub-pathways associated with TNF such as the
NF-κβ response, can be further manipulated by the type of activation (receptor form), the
cellular state and maturity during activation, and subunit diversification of the
transcriptional complex, thus allowing for the modified expression of hundreds of genes,
allowing for the alteration of cellular differentiation pathways and survival fates (Ware
2003).
Chemokines are a distinct set of cytokines with specific structural and functional
characteristics and all share a level of sequence and morphological homology.
Chemokines are defined and divided by structural characteristics and are named based on
variations on the number and sequence of cysteine residues, with most having between
two and four. The conserved sequence and frequency of cysteine residues results in a
highly conserved tertiary structure and non-specific binding of chemokine and receptors
within the same family (Horuk 2001). Chemokines are well known for their role in
neutrophil recruitment and assistance in initiation of a localized inflammatory response.
In addition, chemokines can also function to promote normal and autoimmune
16

inflammatory events (Cravens and Lipsky 2002), immune cell development (Ohl,
Henning et al. 2003), lymphocyte recruitment and activation (Martinez, Gordon et al.
2006), circulatory and nervous system development (Horuk 2001), and as angiogenic and
angiostatic agents (Belperio, Keane et al. 2000).
Several pathogens such as the herpes-simplex virus, poxvirus, and murine
cytomegalovirus have evolved or acquired specific strategies to neutralize cytokine
mediated responses, either through downstream modulation of the immune pathway or
direct competitive inhibition of the chemokine to hinder the development of a proinflammatory response or TNF induced apoptosis (Benedict and Ware 2001). While the
TNF family of cytokines seems to be a common target for pathogen evasion; interferon
and other chemokine functions are also repressed (Rahman and McFadden 2006). In
addition to utilizing cytokine and chemokine antagonists to evade host defense as many
intracellular bacteria, some pathogens such as the Human Immune deficiency Virus
(HIV) and the protozoa Plasmodium have exploited and incorporated these mechanisms
to serve as virulence factors for their own pathogenesis (Catani, Corasaniti et al. 2000;
Lusso 2006). HIV utilizes a remarkable method of chemokine exploitation, whereby it
expresses its cellular receptors in a two stage method incorporating a trimeric
glycoprotein and cellular co-receptors involving CD4 and the chemokine receptor CCR5
or CXCR4. This convoluted strategy allows for the ‘expression’ of the highly conserved
co-receptor binding epitope, while preventing the host from producing neutralizing
antibodies (Labrijn, Poignard et al. 2003), thereby allowing HIV entry into a cell, and
masking conserved non-self regions from antigen presenting cells.
Pathogens such as HIV, poxvirus, Plasmodium, and Salmonella typhimurium have
evolved strategies that utilize our cytokine and chemokine system both against us to
17

evade defenses and to their direct advantage in assisting in targeted cellular infection and
invasion. Another associated ailment surrounding bacterial (particularly gram negative)
pathogenesis is the risk of sepsis or the more severe form, septic shock. Sepsis and septic
shock, collectively referred to as Systemic Inflammatory Response Syndrome (SIRS) is
responsible for over 100,000 human deaths annually and a mortality rate ranging from 25
– 40% within the United States (Blackwell and Christman 1996). Some nonspecific
antigen responses are due to gram positive pathogens, specifically triggered by exotoxins
(Schutte, Mayer et al. 1998) such as Lipoteichoic Acid (LTA) or staphylococcal
enterotoxin B binding to Major Histocompatibility Complexes (MHC) resulting in a
proinflammatory cytokine cascade initiated by Th cells (Weiser and Nahm 2009). The
majority of SIRS induced mortality is due to an autoinflammatory response initiated from
a gram negative bacterial infection, usually initiated by the release and binding of
lipopolysaccarides (LPS) to TLR-4, resulting in macrophage activation and
proinflammatory cytokine release. TNF and IL-1 are two such cytokines implicated in
SIRS, and systemic release, even controlled in response to an infection or endotoxin, can
result in a type of positive feedback loop, resulting in acute inflammation throughout the
body and lethal physiological changes in blood flow and circulation. Endotoxins can be
released in great quantity and concentrations following a successful immune response to
a pathogen resulting in sepsis or septic shock. Treatment options for sepsis and septic
shock are limited; antibiotics and/or antimycotics are used to help curb the underlying
infection, while supportive care is typically administered to stave off death. Considering
the root causes and regulatory components of sepsis, immunotherapy would appear to be
an excellent therapeutic remedy for this autoimmune pathology, however most attempts
at utilizing BRMs have resulted in poor therapeutic outcomes.
18

Most attempts at alleviating sepsis or septic shock via immunotherapy have been
centered on inhibiting various forms of TNF or IL-1, usually via monoclonal antibodies,
soluble receptors, or as in the case with IL-1, a naturally occurring receptor antagonist
which act as competitive inhibitors to both natural forms of IL-1, α and β (Dinarello
1994). Other attempts at immunotherapy have included antagonists to platelet activating
factor, a potent mediator of leukocyte activation and platelet aggregation, bradykinin
antagonists, and cyclooxygenase inhibitors (Remick 2003). While many of these BRMs
have shown promise in pre-clinical trials, little success has been reported in phase II or III
clinical trials, including the much anticipated TNF and IL-1 antagonists. Problems
utilizing TNF and IL-1 theraputically include ambiguity surrounding dosage and
concentrations, proper timing of administration to interfere with the autoimmune process,
improper models and definitions of septic patients within the study, and a general lack of
understanding as to the precise cause and role the immune system plays within sepsis and
septic shock. One notable exception to the overall failure of BRMs and immunotherapy
in the treatment of sepsis and septic shock is the administration of the serine protease
Activated Protein C, a vitamin K dependant anticoagulant (Warren, Suffredini et al.
2002), however, like other immunotherapies, more work is needed to optimize timing,
dosage, and its use for the treatment of sepsis.
Activated Protein C’s role in inflammation, sepsis, and cytokine mediated
inflammation is a prime example as to the difficulties of modulating the intricate system
of cytokine pathways. In the classical route of sepsis, activated macrophages (either via
classical or alternative activation (Gordon 2009)) release TNF, IL-6, IL-8, platelet
activating factor and other proinflammatory mediators; contributing to the sepsis cascade
(Parrillo 2005). IL-1, IL-6, and TNF are also involved in the increased activation and
19

release of Thromboplastin Tissue Factor (TTF) which is responsible for activation of the
extrinsic and intrinsic coagulation pathway and increases thrombin concentrations.
Thrombin’s role in inflammation includes promoting further expression of
proinflammatory cytokines, increased chemokine expression and neutrophil recruitment,
and mast cell degranulation, all contributing to sepsis induced multi-organ failure, a
leading cause of sepsis mortality in humans. Activated Protein C is believed to protect
individuals in late stage sepsis and septic shock by indirectly decreasing thrombin
production via inactivation of coagulation factors, down regulating TTF, and promotion
of Tissue Factor Pathway Inhibitor (Ely, Kleinpell et al. 2003; Short 2004). With proper
dose and temporal considerations it should be possible to treat sepsis with BRMs at an
earlier stage to prevent multi-organ failure and death.
A well studied and characterized model organism for an intracellular bacterial
infection, human typhoid fever, and gram negative induced sepsis via intraperitoneal
injection, is Salmonella enterica. Salmonella enterica serovar Typhimurium (S.
typhimurium) is a common enteropathogenic (Stecher, Robbiani et al. 2007) strain which
is extremely virulent in murine models (Bjorkman, Hughes et al. 1998) and is sometimes
responsible for Salmonellosis in humans. Salmonellosis infects ~1.5 million Americans
annually, 15,000 of which develop severe infections requiring hospitalization.
Transmission can occur from zoonotic transmission, contaminated food is the typical
vector. Salmonellosis is generally easily treated with antibiotics such as fluoroquinolones
and cephalosporins however, increased use of antimicrobials in food animals, livestock,
and companion animals are believed to have increased the natural rate and development
of specific drug resistant strains (Angulo, Johnson et al. 2000; Wright, Tengelsen et al.
2005). S. typhimurium, like many intracellular pathogens, express virulence factors
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which enable them to circumvent or inactivate host defense mechanisms, allowing them
to remain either impervious or unknown to the host organism. S. typhimurium normally
enters the body through ingestion and therefore must transverse epithelial cells of the
intestinal wall before systemic infection can proceed (Jones, Ghori et al. 1994). This is
accomplished by infecting microfold cells which function as a type of APC of the
intestinal lumen, transporting ingested antigens across the follicle-associated epithelium
to an underlying T or B-lymphocyte, macrophage, or dendritic cell (Vazquez-Torres and
Fang 2000). Upon epithelial contact, S. typhimurium causes the cell membrane to
‘wrinkle’ via an actin polymerization reaction which in conjunction with a multicomponent virulence complex known as Type III secretion system, the bacteria is able to
gain entry into the epithelial cell. S. typhimurium ultimately resides and replicates from
within the vacuoles of macrophages (Pamer 2009).
Innate immune defense against S. typhimurium include PRR’s such as TLR’s
which can recognize a wide range of specific antigens associated with the bacteria and
are located on the cellular surface membrane and within macrophage vacuole
compartments where the bacteria resides. PAMP’s associated with S. typhimurium
include LPS, flagellin, non-methylated CpG DNA motifs by TLR-4, 5, and 9,
respectively. However, the role of TLR-5 in the pathogenesis of S. typhimurium is still
debated, as TLR-5 deficient mice seem to offer increased resistance to the pathogen,
presumably from reduced migration from the lamina propria (Uematsu, Myoung Ho et al.
2006; Pamer 2009). Further innate recognition of S. typhimurium occurs within the
cytoplasm and is accomplished with the aid of Nod family of proteins, specifically Nod2.
The Nod family of proteins represents an intracellular pathogen sensing system which
operate independently of TLR’s and appear to operate similarly to R-Proteins, found in
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plants. Both Nod1 and Nod2 belong to a family of proteins known as the nucleotide
binding domain-leucine rich repeats, which are able to recognize, and bind to small
peptidoglycan fragments found within the cytosol. In contrast to Nod1, Nod2 is able to
detect both gram positive and negative intracellular bacteria due to a smaller
peptidoglycan binding motif which does not differentiate between the two. Upon
recognition and binding, Nod2 can induce NFκβ signaling through a serine/threonine
kinase known as RIP2 (Inohara, Koseki et al. 2000; Philpott and Girardin 2004).
Cytokines, specifically IFN-γ play an essential role in an organism’s defense
against intracellular bacterial pathogens, as individuals with mutations effecting IFN-γ,
IFN-γ receptors, IL-12p40, a subunit shared by IL-12 and IL-23, and STAT1, which are
all part of the IFN-γ signaling cascade, all share increased susceptibility or mortality to
many intracellular bacterial infections, like S. typhimurium. IFN-γ seems to be
instrumental in promoting survivability by inducing expression of nitric oxide synthase,
the enzyme responsible for the production of nitric oxide (Courtney and Margo 2004).
IL-12p30, a subunit common in IL-12 but not IL-23, revealed IL-12’s role in Th1 CD Tcell mediated immunity (Courtney and Margo 2004; Pamer 2009) in S. typhimurium
infection.
Control of systemic S. typhimurium is aided by the acute phase inflammatory
response. The primary role of the acute phase response is the restoration of homeostasis
during or after a challenge by tissue injury, infection, or trauma. The acute phase
response can include, but is not limited to; fever, neutrophilia, hypoferraemia, increased
gluconeogenesis and muscle protein catabolism, hormonal changes, and induction of
acute phase proteins (Han 1997). Acute Phase Proteins (APP) are typically
hepatoproteins, synthesized in the liver, and can increase serum protein concentrations by
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several orders of magnitude. Cytokines serve as mediators of the acute phase response,
specifically in the stimulation and regulation of acute phase proteins. APP are divided
into two classes; class I and class II acute phase proteins. Class I APP are induced by the
interleukin-1 family of cytokines, in conjunction with the IL-6 family of cytokines. Class
I APP include Serum Amyloid A (SAA), C-Reactive Protein (CRP), Compliment C3
(C3) and murine haptoglobin. Class II APP are induced by IL-6 like cytokines only, and
include fibrinogen, human (non-murine) haptoglobin, and α1-antichymotrypsin. In
addition to being stimulated by IL-6 cytokines, some type II APP such as fibrinogen may
also be inhibited by the presence of some IL-1 cytokines, and studies have correlated the
expression of IL-1 receptor antagonist and IL-6 in some acute phase reactions, however,
similar studies have shown that IL-1 receptor antagonist does not inhibit the production
of some type I APP in vivo, such as CRP or SAA (Raynes, Eagling et al. 1991; Gabay,
Genin et al. 1995; Han 1997).
APP are essential to an organisms response to microbial infections, and have been
implicated in several discrete functions. APP such as lipopolysaccharide binding protein
(LBP) and soluble CD14 can serve as cofactors for the activation of immune cells
through membrane bound receptors, such as TLR. SAA, LBP, compliment C3, myeloid
differentiation factor-2 and mannose binding lectins can act as direct bacterial opsonins
(Jack, Klein et al. 2001; Shah, Hari-Dass et al. 2006; Tissieres, Dunn-Siegrist et al. 2008)
and other APP such as bactericidal permeability increasing protein (BPI) and compliment
C3 can directly attack and destroy many pathogens. The systemic increase in soluble
APP is also believed to play a role in sepsis, as soluble CD14 and high density
lipoproteins like SAA may act as a sink for endotoxins such as LPS (Viriyakosol, Tobias
et al. 2001) during sepsis.
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Immune Cell Potentiating Factor (ICPF) is a naturally occurring tri-glycosylated
peptide first isolated by equilibrium dialysis with molecular porous membrane tubing
with a molecular weight cut off range of 6-8 kDa from caprine serum (Parker, Willeford
et al. 2005). The preliminary structure of ICPF, a 9 amino acid core consisting of
RSVSLSYRF with 3 conjugated fatty acid side chains of stearate, arachidate,
arachidonate was determined after first being purified to ≥98% from caprine serum using
combined dialysis, ultra-filtration, and Reverse-Phase High Pressure Liquid
Chromatography (RP-HPLC). Structural characteristics (Figure 1) were determined
using combined Edman degradation, standard protease digestions, anion
exchange/reverse phase HPLC, matrix assisted laser desporption/ionization-mass
spectrometry and electrospray ionization-mass spectrometry (Ansley and Willeford 2000;
Thacker, Fuhrer et al. 2004).
Clinical and experimental observations with ICPF isolated from caprine serum
show that it contains one or more components that have an immune modulating effect on
various mammalian and avian organisms. This therapeutic BRM reduced the mortality
evident in murine and avian typhoid, sepsis and cholera models by upwards of 80% when
the subjects were challenged with an otherwise terminal dose of the gram negative
bacteria (Salmonella enterica (serovar typhimurium) and Pasteurella multocida)
(Willeford, Parker et al. 2000; Parker, Willeford et al. 2001; Willeford, Parker et al. 2001;
Parker, Willeford et al. 2005). In association with an increased time to death and
survivability of test subjects, a significant reduction in the splenic bacterial load in treated
mice was observed. Fractions containing the desired component(s) in question have
shown a wide range of attributes which prompted further study. In addition to the
reduced mortality in avian and murine subjects against Salmonella typhimurium, a
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reduction of tumorogenesis in a murine melanoma model (Parker, Willeford et al. 2005)
was also documented.

Figure 1

Chemical and mass spectral fragmentation of ICPF

Key ion fragments in the MALDI-MS electro spray MS are indicated where R1 is
stearate, R2 is arachidate, and R3 is arachidonate. Figure created with aid of ChemOffice
2000 (Cambridge Soft) (Ansley and Willeford 2000; Thacker, Fuhrer et al. 2004)
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CHAPTER II
PROPHYLACTIC EFFECTS OF IMMUNE CELL POTENTIATING FACTOR
DERIVED FROM NON-CAPRINE MAMMALIAN SPECIES AND
EVALUATION OF BACTERIAL AND VIRAL PATHOGENESIS
THROUGH ANIMAL MORTALITY MODELS
Introduction
The prophylactic properties of caprine-serum derived ICPF have been studied in
detail over the last several years within our laboratory (Willeford, Parker et al. 2000;
Willeford, Parker et al. 2001; Parker, Willeford et al. 2005); and questions concerning
efficacy, temporal and dosage requirements, and stability and safety considerations have
been addressed and whenever possible, resolved. However, several key questions
stemming from this work have remained unanswered. ICPF had only been isolated and
validated from caprine serum samples, yet caprine derived biologicals pose a potential
zoonotic biohazard, as bovine spongiform encephalopathies and other prion related
neurological diseases are believed to have originated from caprine and ovine sources
(Agrimi, Conte et al. 2003; Valdez, Rock et al. 2003). To circumvent these potential
biohazard concerns as well as possible complications associated with allergic or immunecomplex (type III) hypersensitivity reactions (Sarah, Lisa et al. 2004) we attempted to
isolate and validate ICPF from additional mammalian hosts; specifically equine, bovine,
porcine, and human. Previous animal and immunological studies have been centered on
minimal terminal dosage experiments and mainly focused on alleviation of mortality to S.
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typhimurium. In an effort to address specific questions pertaining to ICPF’s mode of
action we tested the drug’s efficacy against S. typhimurium’s predominant endotoxin,
lipopolysaccharide (LPS). LPS, while not the only S. typhimurium derived agent known
to illicit an immune response, is by far the predominant endotoxin responsible for
bacteremia induced systemic inflammatory response syndrome; toxic shock syndrome.
Gram-negative bacteria, in particular via endotoxin release upon lyses, are responsible for
septic shock and toxic shock syndrome, resulting in multi-organ failure and ultimately
death (Nicoletti, Di Marco et al. 2001; Lynn, Rossignol et al. 2003). ICPF, while known
to reduce mortality as well as splenic bacteria counts, has not been evaluated or shown to
protect against LPS induced endotoxemia and its associated organ failure. Evaluation of
ICPF effectiveness against an endotoxin such as LPS, if successful in alleviation of
mortality, would simplify experimental bioassay design and shed new light in a possible
mode of action of this immunomodulatory peptide. To address both these questions,
previously validated ICPF was prophylactically administered to Specific Pathogen Free
(SPF) Swiss Webster Mice challenged with an otherwise lethal dose of inter-peritoneal
administered LPS as well as cultured S. typhimurium at 3 fold the standard challenge
dose of 5 x 103 CFU.
ICPF was further evaluated for effectiveness as an immunotherapy in the
treatment of canine patients afflicted with Type-2 Canine Parvovirus (CPV-2). CPV-2 is
a small, non-enveloped virus responsible for potentially fatal gastroenteritis in canines, as
well as felines in the form of the closely related and potential origin of CPV-2, feline
panleukopenia virus (Decaro, Martella et al. 2006; Spibey, Greenwood et al. 2008).
There has been little direct evidence that ICPF would be beneficial against additional
pathogenic agents such as gram-positive bacteria or viral challenges; however the
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presumed non-pathogen specific mode of action and ICPF's apparent ability to potentiate
overall immune function presented substantial circumstantial evidence towards possible
efficacy for supportive treatment of viral associated diseases. We chose to test ICPF in
clinical trials against naturally infected parvovirus type-2 canines in hopes of alleviating
secondary post-infections associated with opportunistic pathogens in immune
compromised individuals, possible antiviral properties stemming from a modulated
immune response, and increasing survival by assisting in the supportive care. In addition
to the clinical analysis of the immunotherapuric properties of ICPF, the antiviral and
virucidal properties of ICPF where determined by hemagglutination assays of A-72
canine fibroblast cells.
Materials and Methods
Murine Animal Care and Maintenance
Specific Pathogen Free (SPF) female Swiss Webster mice were purchased from
Charles River Laboratories (Wilmington, MA). Mice were allowed to acclimate for 2
weeks upon arrival, during which time they were fed a standard maintenance diet
(Laboratory Rodent Diet 5001; PMI Nutrition, Richmond, IN) and watered ad libitum.
Mice were group-housed (5 mice per cage) in plastic boxes bedded with wood shavings
in an American Association for the Accreditation of Laboratory Animal Care
(AAALAC)-accredited facility. Mice were then transferred to an isolation room
immediately prior to inoculation with S. typhimurium or S. typhimurium derived
lipopolysaccharides. Experiments were carried out individually so as noninfected/challenged individuals never came in contact or exposed to challenged mice.
The isolation room was maintained at 20° C in a controlled negative pressure
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environment on a 12-h lighting cycle. Animal care and use were in accordance with the
policies of the Institutional Animal Care and Use Committee of Mississippi State
University protocol number 05-051.
Bacterial Culture
S. typhimurium (ATCC 14028) was used as a challenge organism after passage
through a murine host no less than three times with subsequent isolation and storage in
Dulbecco PBS (dPBS) with 10% glycerol at –80° C. This isolate was supplied from a
stock culture from the Department of Biological Sciences (Mississippi State University),
where it is maintained as a reference organism. Bacterial counts and CFU’s were
determined by culturing 20 μl of S. typhimurium (ATCC 14028) in 10 mL of Brain Heart
Infusion Broth at 37° C for 24 hours on an orbital shaker, prior to serial dilution with
sterile Dulbecco phosphate buffered saline (dPBS). Salmonella typhimurium growth
curves were determined by inoculation of 50 mL Brain Heart Infusion broth (prepared to
manufactures specification) by 20 μl stock S. typhimurium. At 30 minute intervals 100 μl
was removed and diluted with 900 μl of ddH2O (1:10 dilution) and the optical density
measured (referenced against a 1:10 dilution of BHI), plot was fitted with a 5-parameter
sigmoidal function (SyStat 2008) (Figure 2). Live bacteria counts were determined by
counting Colony Forming Units (CFU) generated by inoculation of 20 μl S. typhimurium
taken from the cultures stationary phase and cultured on 1.5% agar BHI plate following
seven 1:10 serial dilutions. In all cases (unless stated otherwise), bacterial cultures were
diluted to 2.5 x 104 CFU per mL, allowing for 5 x 103 CFU per 0.1 mL ip injection and
actual inoculations determined by plates following administration.
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Determined by inoculation of 50 mL Brain Heart Infusion broth (prepared to
manufactures specification) with 20 μl stock S. typhimurium. At 30 minute intervals 100
μl was removed and diluted with 900 μl of ddH2O (1:10 dilution) and the optical density
measured (referenced against a 1:10 dilution of BHI), plot was fitted with a 5-parameter
sigmoidal function (SyStat 2008) resulting in an R2 value of 0.099 and a standard error of
estimate of 0.026.
Lipopolysaccharide Mortality Model
S. typhimurium derived lipopolysaccharide was purchased from Biogenesis, Inc.
(Kingston, NH) To induce lethal endotoxemia, LPS was diluted with dPBS to 500
μg/mL and 50 μg LPS (2.5 mg/kg) was administered via a 0.1 mL ip injection. This
dosage of LPS was determined by previous experiments and defined by its capability to
induce mortality in 80 – 100 % of mice within 3-4 days (Muchamuel, Menon et al. 1997).
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ICPF Preparation
ICPF was prepared by equilibrium dialysis utilizing a semipermeable 6-8K
molecular weight cut off dialysis membrane (Spectrum Laboratories, Rancho
Dominguez, Ca). Serum taken from caprine, bovine, equine, porcine, and human subjects
underwent dialysis for 24 hours at 4° C at a 1:10 ratio against sterile double distilled deionized water. Following dialysis, effluent was lyophilized and stored at -80° C.
Lyophilized material was determined to be +95% protein by weight as per the Bradford
(BioRad™, Hercules, Ca.) and Micro Bicinchoninic Acid (Pierce; Rockford, IL) protein
determination assays.
Virucidal and Cytotoxic Experimental Design
The virucidal and antiviral interactions between ICPF and CPV-2 were assessed
by ViroMed Biosafety Laboratories (St. Paul, MN). In the virucidal assay, CPV-2
(obtained from ATCC: VR-2017) was incubated with 4 log dilutions of ICPF (0.1 to 100
μg/ml) for four hours and then added to wells containing canine fibroblast A-72 cells (test
wells). Wells were also established to represent a cell control (cells which were neither
exposed to CPV or ICPF) and virus control (cells which were exposed to CPV following
incubation with culture medium). Prior to inoculation, cells were microscopically
determined to be 30 – 50% confluent, and in optimal condition for CPV infection.
Following incubation of the cells for 12 days, the supernatants from the cell control, virus
control and ICPF treated wells were assayed for virucidal activity using a
hemagglutination assay. To determine whether ICPF was directly cytotoxic to the canine
fibroblasts, cells were plated and exposed to ICPF. After incubating for 12 days, the
wells were assessed for cellular proliferation using a Microculture Tetrazolium Assay
(Delhaes et al., 1999). For the antiviral assay, canine fibroblast A-72 cells were exposed
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to CPV-2 for two hours and then either ICPF (up to 100 μg/ml) or culture medium was
added to establish the treated and virus control samples. Wells plated with cells that had
not been exposed to CPV or ICPF were used to establish a cell control well. Cells were
incubated for 10 days and their supernatants assayed for viral infectivity using a
hemagglutination assay. Tissue Culture Infectious Dose per mL (TCID50/mL) was
calculated for each titration using the Spearman-Karber method (Svensson, Hjalmarsson
et al. 1999). To test ICPF for erythrocyte hemolysis, canine erythrocytes were collected
and separated via centrifugation for four minutes at 2000 RCF (relative centrifugal force),
the top two layers decanted, and the remaining erythrocytes washed three times with
dPBS. dPBS was then added to the cells to make a 10% (v/v) suspension, ICPF was
prepared in dPBS and added to concentrations ranging from 0.001 - 1.0 mg/mL (Table 2)
and incubated for 30 minutes. A positive control consisting of erythrocytes completely
hemolyzed by the addition of 0.2% (v/v) Triton X-100 (Chow, Hedley et al. 2005) was
compared to erythrocytes in dPBS and measured spectrophotometrically at 415 nm.
Murine ICPF Experimental Design
Mice comprising the (positive) control and treated populations were injected ip
with 0.25 ml of S. typhimurium (~5 x 103 CFU/mouse) or 0.1 ml (50 μg) S. typhimurium
derived LPS on day 0. Unless stated otherwise, treated mice were given a 0.2 ml ip
injection of ICPF (25 mg protein/ml) at the time designated by the experimental protocol,
while control mice received a placebo of physiological saline. Negative control mice
were sham-handled in a similar manner to the control and treated populations to evaluate
the influence of non-experimental parameters on mortality. Mice were housed up to five
per cage and a minimum of six cages were used per treatment group in a randomized
32

block design. Mice were monitored three times daily and mortality recorded until 80% of
the control mice died or for a maximum of 2 weeks.
Canine Virucidal ICPF Experimental Design
Dogs which were diagnosed by both physical examination and ELISA fecal
analysis (IDEXX, Westbrook, ME) with parvoviral enteritis where upon admission to the
study randomly assigned to either a placebo (n = 25) or ICPF (n = 25) treatment group.
Supportive care was initiated and 5 mg of ICPF or dPBS was administered to the
respective groups by a 0.5 mL subcutaneous injection. This was a double-blinded study,
with neither the researchers or the attending veterinarian and personal staff aware as to
the identity of the test articles and groupings until termination of the study. Severity of
the disease upon diagnosis was determined by assessing the following parameters:
diarrhea (0 – 3) where 0 = none, 1 = mild (soft-formed stool), 2 = moderate (runny stool),
and 3 = severe (loose stool with excessive mucous/blood); apathy (0 – 2) where 0 = none,
1 = mild to moderate, and 2 = severe depression/comatose; vomiting (0 = no, 1 = yes),
fever (0 = no, 1 = yes), and overall assessment of presenting condition (0 – 3 ) where 0 =
no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.
All animals were placed in an isolation ward (Collierville, TN) and supportive care
included; intravenously provided cefazolin (22 mg/kg every 8 hours) to combat bacterial
infection, metoclopramide (0.5 mg/kg every 8 hours) to normalize gastrointestinal
peristalsis and reduce vomiting, and 5% dextrose lactated Ringers solution with 20 mEq
(mmole) KCl/L.
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Statistical Analysis
All experiments were arranged in a completely randomized block design. A
Kaplan-Meier survival analysis was conducted for data from each survival study utilizing
the LIFETEST procedure in SAS for Windows version 9.2 (SAS Institute, Car, NC).
When survival plots containing more than 2 curves where required, an adjustment based
on Tukey’s studentized range test was used. P-values were calculated using Log-Rank or
Wilcoxon methods and P-values <0.05 were considered significant.
Results
Lipopolysaccharide Mortality Model
To investigate the potential therapeutic properties of caprine derived ICPF in vivo
against LPS induced endotoxemia an animal mortality model was developed. LPS acts as
a potent endotoxin upon bacterial cell lyses, and is the predominant cause of death in
patients systemically infected with several gram negative bacterial pathogens (Klut,
Whalen et al. 2001), including food borne Salmonellosis, and E. coli. Effectiveness in
reducing mortality in S. typhimurium challenged mice was previously established in our
laboratory (Willeford, Parker et al. 2001), however an early immune response towards
the bacteria which curtailed infection and thereby reduced LPS toxemia or a direct mode
of action, perhaps relating to an early humoral response has never been determined. In
this study however, ICPF was not significantly therapeutic to S. typhimurium derived
LPS induced endotoxemia, despite its ability to alleviate mortality in a similar gramnegative challenged mouse model (Figure 3). In fact, ICPF treated mice fared worse than
their non-treated counterparts, with an 80% increase in time to death and a 7% increase in
mortality over the course of the study.
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Figure 3

Effect of S. typhimurium derived lipopolysaccharide on ICPF treated mice.

Control mice –●– were challenged ip with 0.1 ml (50 μg) S. typhimurium derived LPS on
day 1, while treated ⋯○⋯ mice received both 0.1 ml (50 μg) S. typhimurium derived
LPS and a 0.2 mL ip injection of ICPF (5 mg) on day 0. Each data point represents the
cumulative percent survival (n = 20), *p > 0.05.
Therapeutic Properties of Bovine, Equine, and Human Derived ICPF on Salmonella
typhimurium infected Mice
To ascertain any potential therapeutic properties of ICPF derived from noncaprine, mammalian animals, ICPF purified from Bovine, Equine, and Human serum was
tested in a S. typhimurium animal mortality model (Bovine data not determined in this
study, and therefore not included, but results were similar). Serum from the
aforementioned species was processed in an identical manner as validated caprine ICPF,
as previously described. One day prior to challenge by 5 x 103 CFU of S. typhimurium, 5
mg of ICPF from Bovine, Equine, and Human serum was administered ip in 0.1 mL
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physiological saline. Previously validated caprine ICPF was also administered to serve
as a positive control group. A negative control group consisted of challenged mice which
were sham handled and injected ip with 0.1 mL physiological saline. Mortality began 6
days post challenge in the negative control and rose to 86% on day 8. As can be seen
(Figure 4) mortality of mice treated with caprine derived ICPF also began on day 6,
however there was an 80% reduction in mortality, and by day 8, when mortality reached
86% for the negative control, the positive control had reached 13%. Both the human and
equine derived ICPF followed this trend, with little deviation. The only divergence being
an additional two day delay for time to death for equine derived ICPF, which was not
deemed significant (P > 0.05). Total reduction of mortality for human and equine ICPF
after 8 days was a 73% and 83%, respectively.
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Figure 4

Effect of equine and human derived ICPF on S. typhimurium challenged
mice

Negative control mice –●– were challenged ip with 0.1 ml (~5 x 103 CFU) S.
typhimurium on day 1, while equine derived, ⋯○⋯ human derived, --▼-- ICPF treated
mice received both 0.2 mL (~5 x 103 CFU) S. typhimurium on day 1 and a 0.2 mL ip
injection of ICPF (5 mg) on day 0. Previously validated caprine derived ICPF ––––
served as a positive control, and received both 0.2 mL (~5 x 103 CFU) S. typhimurium on
day 1 and a 0.2 mL ip injection of ICPF (5 mg) on day 0. Each data point represents the
cumulative percent survival (n = 20), *p < 0.001 and ** p > 0.05.
Increased Bacterial Load (15,000 CFU)
Previous examinations of ICPF centered on the peptide’s ability to alleviate,
reduce, or postpone mortality in mice challenged with a terminal dose of S. typhimurium,
specifically 5 x 103 CFU which corresponds to an LD80 within 8 days post-exposure.
ICPF has shown considerable consistency in reducing mortality at this dose, however the
immune response necessary to alleviate morbidity or mortality may differ depending on
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the dosage received (Hormaeche 1979) and may correlate with ICPF’s activity and
potency. In this study, two groups of 6 – 8 week old Swiss-Webster mice were
inoculated ip with 1.5 x 104 CFU of S. typhimurium, a 3-fold increase to our standard (5 x
103 CFU) LD80 over 8 days (Figure 5). The negative control mice were sham handled
and received 0.1mL dPBS, while a positive control received 5.0 mg ICPF ip. Mortality
initiated five day's post exposure, and reached 95% in seven days within the negative
control. We observed a 60% reduction in mortality for treated mice at eight days post
exposure.
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Figure 5

Increased bacterial challenge on ICPF treated mice.

Negative control mice –●– were challenged ip with 0.1 ml (~5 x 103 CFU) S.
typhimurium on day 1, while ICPF treated mice ⋯○⋯ received both 0.2 mL (~5 x 103
CFU) S. typhimurium on day 1 and a 0.2 mL ip injection of ICPF (5 mg) on day 0. Each
data point represents the cumulative percent survival (n = 20), *p < 0.001.
Double Blinded Clinical Canine Parvo-Virus ICPF Analysis
Dogs entering the study demonstrated a reluctance to eat prior to admission and
upon presentation. ICPF treated dogs show 68% survival versus 32% for dogs in the
placebo group, representing a 2.1 fold increase in survival for animals receiving ICPF
augmented treatment. Difference in mortality was significant (P = 0.01) when group
comparison statistics were performed. Significance was maintained if animals which
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died within a 24 hour time period from either study group were removed from the study
population (P = 0.006). There were two such cases within the ICPF treatment group and
three within the placebo group, the adjusted measure of survival was 74% and 36%,
respectively. Upon admission to the study, 13 dogs were evaluated with severe diarrhea
(9 within the placebo group, only one survived). Significance was again sustained (p =
0.015) if the dogs which succumbed to parvo-viral enteritis under these conditions were
removed from the study population, with 81% of the animals in the ICPF treatment group
surviving versus 47% in the placebo group. If an animal’s death ensued after presenting
with severe diarrhea upon admission to the study or within 24 hours of admission the
survival measure was 50% and 85% for the placebo and ICPF treatment groups,
respectively, statistical significance was again noted (p = 0.033) (Figure 6).
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Survival analysis of canines treated with ICPF following diagnosis with
parvoviral enteritis

Dogs which received supportive care, denoted ∎ consisting of 5 mg ICPF administered
sc and ∎ denote dogs were given a placebo consisting of 0.5 mL dPBS sc. Base analysis
represents survivability of dogs without exclusion of individuals presenting with severe
diarrhea or early mortality (p = 0.010). Analysis 1 represents total survivability after
removal of individuals from study due to mortality within 24 hours post admission (p =
0.006). Analysis 2 represents total survivability after removal of individuals from study
which presented with severe diarrhea upon administration of the study (p = 0.015).
Clinical and Experimental Antiviral/Virucidal Properties of ICPF
Cytotoxicity to ICPF was tested in situ by incubating an immortalized line of
canine fibroblast cells for 12 days with ICPF concentrations ranging from 0.001 µg/mL
to 10.0 mg/ml. These cells showed little adverse effects (as determined by cell viability
and proliferation) after exposure to ICPF (Figure 7) with percent proliferation ranging
from 75% to 202%. ICPF was not virucidal to CPV at concentrations ranging from 0.001
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µg/mL to 1 mg/mL, as infectivity and proliferation of CPV was not affected by prior
exposure to ICPF as determined by erythrocyte hemagglutination (Table 2A). Average
TCID50/mL of CPV virus control wells was determined to be 3.16 x 103. Under the
conditions of this assay, a one log reduction in virus production was present in samples
incubated with 10 mg/mL ICPF (3.16 x 102 TCID50/mL) while no other ICPF
concentration resulted in a reduction of CPV titers. Red blood cell hemolysis testing was
performed on ICPF to determine the degree to which ICPF may induce hemolysis of
erythrocytes, a simple and versatile in vitro indicator of drug cytotoxicity. This was
performed in partial fulfillment of a drug safety profile for the US Federal Drug
Administration. ICPF was shown not to induce erythrocyte hemolysis at concentrations
ranging from 1.0 – 0.001 mg/mL (Table 2B).
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Figure 7

Cytotoxicity of ICPF on canine A-72 fibroblast cells.

ICPF was administered to A-72 Fibroblast cells at concentrations ranging from 1 x 10-6 to
10 mg/mL. Percent cellular proliferation ranged from 75.3% to 202.7%. Cellular
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proliferation was measured using a microculture tetrazolium assay, using 2,3bis(2methoxy-4-nitro-5-sulfophenyl)-5-(phenyl-amino)-cabonyl-2H-tetrazolum
hydroxide
(XTT), viable cells metabolize XTT, producing a soluble formazan dye. Percent cellular
proliferation was measured as a mean of toxicity/mean of cell control (cells not exposed
to ICPF) ± S.E.M of n=3.
Table 2

Effect of ICPF on CPV proliferation and Erythrocyte Hemolysis

A.

B.

ICPF Concentration
Virus Controls
10 mg/mL
1.0 mg/mL
0.1 mg/mL
0.01 mg/mL
0.001 mg/mL
0.0001 mg/mL
0.00001 mg/mL
0.000001 mg/mL

CPV (TCID50/mL)
3.16 x 103
3.16 x 102
3.16 x 103
3.16 x 103
3.16 x 103
3.16 x 103
3.16 x 103
3.16 x 103
3.16 x 103

Sample
1
2
3
Avg. % Hemolysis
Positive Control
0.135
0.131
0.134
0.133
100
Negative Control
0.002
0.003
0.002
0.002
0
0.001 mg/mL
-0.001 -0.001 -0.002 -0.001
0
0.01 mg/mL
-0.001 -0.002 -0.002 -0.002
0
0.1 mg/mL
-0.003 -0.002 -0.002 -0.002
0
1 mg/mL
-0.002 -0.002 -0.003 -0.002
0
A. TCID50/mL as determined by erythrocyte hemagglutination. Wells positive for CPV
in the presence of erythrocytes are characterized by the formation of a proteinaceous
lattice over the bottom of the well. B. Canine erythrocytes incubated in 0.2% Triton X100 served as a positive control and spectrophotometric reference for erythrocyte lysis
while cells incubated in a 10% dPBS solution served as a negative control. Percent
hemolysis was calculated using the equation (Sample Absorbance at 415 nm – Negative
Control)/(Positive Control-Negative Control) x 100. ICPF did not induce erythrocyte
lysis at any concentration ranging from 0.001 – 1.0 mg/mL.
Discussion
When considering any new therapeutic agent, especially one which appears to
work as a biological response modifier, it is important to consider its broader range of
activity, often beyond the compounds intended or anticipated medicinal roles. With this
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in mind, we entered into this portion of our investigation with an emphasis on further
elucidating relative safety, toxicity, and increased range of activity with respect to
pathogenic presentation and cross species interactions. When looking beyond the
preconceived roles of any therapeutic, it is often prudent to concurrently address any
potential problems. Risk associated with systemic bacterial infections are often two fold;
systemic proliferation of the bacteria and endotoxins, such as LPS, released following
elimination and lyses by the associated immune response and any antibiotics
administered. ICPF appears to act as an immune modulator, with increased immune
effectiveness 24 hours prior to exposure of a bacterial challenge. This was reestablished
indirectly by ICPF’s inability to alleviate LPS associated mortality. It is known that the
balance between systemic levels of pro and anti-inflammatory cytokines play a key role
in the severity and outcome of S. typhimurium associated sepsis (Walley, Lukacs et al.
1996), it is of little surprise that an immunotherapy which is believed to operate by
potentiating an early immune response would be of limited use in an LPS induced sepsis
model. Previous studies (Tracey, Fong et al. 1987; Block, Berg et al. 1993) have shown
reduction of pro-inflammatory cytokines, by monoclonal antibodies or receptor
antagonists, or the administration of anti-inflammatory cytokines to offer protection
against endotoxemia or septic shock. Current evidence suggests that ICPF acts in a
manner to increase early pro-inflammatory cytokine response, which aid in keeping
pathogenic bacteria concentrations at a level manageable by the immune system.
ICPF derived from caprine serum has shown both consistency and reliability in
activity and function, however caprine derived biologicals are under increasing
surveillance and restrictions by the USDA. Additional active mammalian sources of
ICPF would be beneficial in further understanding the biological role of ICPF and to
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assuage concern with respect to its accepted use. The confirmation of immunological
activity in ICPF derived from bovine, equine, canine and human serum suggests a role
fundamental to the mammalian immune response. The presence of non-mammalian
ICPF has not been reported, however mammalian ICPF has been validated within our
laboratories to illicit an immune response and offer protection in avian subjects
(Willeford, Parker et al. 2000). The presence of active ICPF across several mammalian
species in conjunction with biological activity within avian test subjects suggests a mode
of action shared by mammals and birds. Within mammals there exists considerable
homology within Toll-Like Receptor structure and function and while differences exist
between human and mice (Table 1), these difference are usually the result of gene
duplications. The presence of ICPF in several mammalian species, ranging from human
to goat, all of which are able to potentiate an immune response in mammalian and avian
test subject, strongly suggests an evolutionarily primitive pathway, related to the innate
immune response, such as TLR. Direct evidence linking ICPF function and TLR, would
require proof of either a direct (ICPF-receptor) mediated response or confirmation of its
emanate cytokine cascade.
ICPF has been shown to be non-virucidal against CPV-2 and does not interfere
with the virus’ ability to infect or proliferate within tested cell types, specifically canine
A-72 fibroma cells. In what was the first double blinded study to characterize the
therapeutic effects of ICPF in a viral challenge, ICPF reduced canine mortality by 36%, a
(p = 0.010) significant amount. It is clear from the data provided that ICPF promotes
resistance to CPV infection without acting as a directly virucidal agent, the mechanism
by which it accomplishes this remains to be elucidated. It is possible that ICPF provokes
a PRR mediated response to the viral presence or perhaps rallies the immune system
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giving the subject the time it needs to circumvent death while developing permanent
immunity to CPV. The results of this study, while providing new and valuable insight to
ICPF potential as an antiviral therapeutic, does not address specific questions concerning
mode of action or efficacy. What this study has shown however, is a direct correlation
between specific immune pathways and clinically relevant results. Mortality associated
with CPV-2 infections rarely result from the virus itself in individuals infected prior to 8
weeks of age (Greene 1984). Mortality is usually proceeded by hemorrhagic enteritis,
myocarditis, secondary infections, and gram negative sepsis (Greene 1984; Wessels and
Gaffin 1986; Evermann, Abbott et al. 2005), followed by disseminated intravascular
coagulation and death. Pathogenesis resulting in death in dogs over 8 weeks of age may
take one of two routes; CPV infections of lymphoid tissue and marrow or infection within
epithelial cells particularly within the crypts of the small intestines (Favrot, Olivry et al.
2000). Dogs with CPV infected lymphoid tissue suffer from associated
immunodeficiency resulting in secondary infection and gram-negative sepsis. Intestinal
epithelial cell infections usually result in increased intestinal permeability, resulting in a
drop of colloidal pressure and fluid loss, and decreased nutritional absorption, ultimately
followed by either recovery or secondary infection and sepsis, the later usually resulting
in death by disseminated intravascular coagulation. ICPF intercedes in this process by
either interfering with viral pathogenesis, moderating the secondary affects resulting from
immunodeficiency, or through tempering both these activities.
We have previously shown that ICPF does not protect mice suffering from acute
gram-negative derived endotoxemia, (Figure 3) yet is capable of assisting compromised
individuals suffering from systemic bacteriameia (Figure 5) when prophylactically
treated. This study, being clinical in nature, was not designed or intended to differentiate
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between sepsis induced by inflammation of the gastrointestinal tract or
immunodeficiency, and we are therefore limited in our ability to attribute a specific
systemic mode of action to ICPF in CPV-2 infected dogs. ICPF’s ability to alleviate
mortality in such a model does further establish its role as an immune potentiator and
suggests additional clinical uses in both human and veterinary medicine, possibly as an
adjuvant for the treatment of immune stressed/compromised individuals or patients at risk
of severe inflammatory reactions as seen in CPV patients. Further work utilizing a
different viral model, specific pathogen free animals, and a better understanding of the
specific immune response to ICPF may clarify the full extent of ICPF’s bioactivity and
mode of action.
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CHAPTER III
SYSTEMIC IN VIVO PROTEOME CHANGES RESULTING FROM
ADMINISTRATION OF IMMUNE CELL
POTENTIATING FACTOR
Introduction
ICPF mediated prophylaxis to a systemic S. typhimurium infection has been
shown to display both temporal and dose dependencies (Parker, Willeford et al. 2001).
These time and dosage considerations of successful treatments can be indicative of a
systemic proteomic shift as well as underlining ICPF’s immunological mode of action. A
medium time frame of 24 hours pre-infection for peak immunological performance was
determined for the administration of ICPF in specific pathogen free (SPF) female Swiss
Webster Mice and therefore, the first 24 hours serves as an ideal initial time frame to
monitor for such changes. A pre-challenge window of 24 hours makes an adaptive or
humoral response within that time frame unlikely, however it may be indicative of an
innate mediated inflammatory response (Medzhitov 2009).
Systemic proteomic shifts in response to traditional drugs are somewhat rare and
undesirable, nevertheless an immune initiated acute phase response would be possible
and fitting based on known prophylactic time frames. In order to determine if ICPF had
any systemic effects on various protein concentrations and profiles, several experiments
were conducted. To determine the effect of ICPF on Acute Phase Proteins (APP), Serum
Amyloid A concentrations were determined following ICPF treatment with and without a
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bacterial challenge. APP are an ideal staging point to search for possible systemic
proteomic changes related to immunity, as serum levels of APP can increase 1,000 fold
within minutes of an inflammatory incident, (Beer, Baltz et al. 1982; Raynes, Eagling et
al. 1991). While the chemical trigger initiating APP production (e.g, cytokines) will
spike temporally (providing a detection window of perhaps minutes) APP increases can
persist for hours or days. These collective features make APP detection straightforward,
while if discovered, simultaneously validating the impetus to seek its trigger.
The roles of APP are complex, ranging from initiation of compliment,
opsonization, homeostasis, lipid transport, and immune cell activators but are, by
themselves, of limited use in further elucidation of ICPF’s mode of action (Szalai,
VanCott et al. 2000; Shah, Hari-Dass et al. 2006; Tissieres, Dunn-Siegrist et al. 2008).
Their diverse functions open the door to more complex and specific proteomic changes
within the body. To better understand the homeostatic and physiological changes
associated with ICPF, a more inclusive and quantitative examination of differential
proteome profiles is required. To facilitate this need, proteomic changes associated with
ICPF were mapped out in serum, spleen, lung, liver, and central nervous tissue (brain)
using Two-Dimensional Fluorescence Difference in Gel Electrophoresis (2D DIGE).
Serum was evaluated for proteomic changes for it serves as a conduit for nearly all
endocrine and immune signaling, is essential for swift bacterial dissemination within the
body, and on the forefront of the innate immune response. Splenic tissue was evaluated
as it represents the largest single organ of the immune system. Respiratory (i.e., lung)
tissue was selected for proteomic examination as ICPF showed promise in alleviation of
equine lower respiratory disease in vivo (Hamm, Willeford et al. 2002) and alveolar
macrophage activation in vitro (unpublished). The innate immune response is specific to
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the lung – wherein this large respiratory surface area is constantly being exposed to
inhaled particles and microorganisms. Central nervous tissue was examined to assess
physiologic changes related to immune function and homeostasis. Brain and liver (the
latter being the primary site of APP production) also serve as a more stable platform to
monitor proteomic changes in contrast to the dynamic nature within the circulatory
system.
Materials and Methods
Murine Animal Care and Maintenance
Specific Pathogen Free (SPF) female Swiss Webster mice were purchased from
Charles River Laboratories (Wilmington, MA). Mice were allowed to acclimate for 2
weeks upon arrival, during which time they were fed a standard maintenance diet
(Laboratory Rodent Diet 5001; PMI Feeds) and watered ad libitum. Mice were grouphoused (5 mice per cage) in plastic boxes bedded with wood shavings in an American
Association for the Accreditation of Laboratory Animal Care (AAALAC)-accredited
facility. Mice were then transferred to an isolation room immediately prior to inoculation
with S. typhimurium or S. typhimurium derived lipopolysaccharides. Experiments were
carried out individually so as non-infected/challenged individuals never came in contact
or were exposed to challenged mice. The isolation room was maintained at 20° C in a
controlled negative pressure environment on a 12-h lighting cycle. Animal care and use
were in accordance with the policies of the Institutional Animal Care and Use Committee
of Mississippi State University protocol number 05-051.
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Murine Treatments and Sample Collection
Two groups of SPF female Swiss-Webster Mice (n=3 per group) comprising a
treated population and (negative) control were injected ip with either 5 mg of previously
validated caprine ICPF in 0.2 mL dPBS or 0.2 ml dPBS, respectively. Following
administration of treatment or placebo, one individual from each group was sacrificed at
0, 3, and 24 hours by CO2 asphyxiation and 0.8 - 1.0 mL of blood drawn by cardiac
puncture. Whole blood was transferred into a 5 mL sterile serum tube, gently inverted
several times, placed upright and allowed to clot at ~25° C for 30 - 45 minutes. Samples
were then centrifuged for 10 minutes at 1,500 RCF. 50 - 100 μl serum were collected
with a micropippette and stored at -80° C. Cardiac, liver, respiratory, spleen, CNS (e.g.,
brain), and ocular tissue where then aseptically removed and stored at -80° C for further
analysis.
Serum Amyloid A Experimental Design and Analysis
Three groups of SPF female Swiss Webster Mice (n=5 per group) were utilized in
this experiment. Group 1 received 5 mg ICPF ip in 0.2 mL dPBS, while a second group
received 5 x 103 CFU ip of S. typhimurium and the final group received 5 mg ICPF ip in
0.2 mL dPBS 24 hours prior to 5 x 103 CFU ip of S. typhimurium. An additional group
consisting of n=5 served as a baseline and negative control for comparison, were sham
handled and received 0.2 mL dPBS. At 6, 24, and 48 hours following challenge of S.
typhimurium, the mice were sacrificed by CO2 asphyxiation and 0.8 - 1.0 mL of blood
was drawn by cardiac puncture. Whole blood was transferred into a 5 mL sterile serum
tube, gently inverted several times, placed upright and allowed to clot at ~25° C for 30 45 minutes. Samples were then centrifuged for 10 minutes at 1,500 RCF. 50 - 100 μl
serum were collected with a micropippette and stored at -80° C. Serum Amyloid A
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values were determined using a solid phase sandwich ELISA (Tri-Delta Diagnostics,
Rockaway Valley, NJ) and a streptavidin-HRP conjugate in a 96 well microplate format.
2D DIGE Tissue Preparation
Respiratory (lung), liver, central nervous tissue (brain), and splenic tissue were
washed with Washing Buffer (10 mM Tris-HCl and 5 mM magnesium acetate, pH 8.0) in
order to remove contaminates such as extraneous tissue and blood. 200 μl of 2D cell
lysis buffer (30 mM Tris-HCl, pH 8.8, containing 7 M urea, 2 M thiourea and 4%
CHAPS) were mixed with 10 mg of tissue sample and sonicated at 4° C. Samples where
then centrifuged for 30 minutes at 10,000 RFC and supernatant collected. Protein
concentration was determined by either the Bradford (BioRad™, Hercules, Ca.) or Micro
Bicinchoninic Acid (Pierce; Rockford, IL) protein determination assays. Samples were
diluted to between 4 - 8 mg/mL.
2D DIGE Proteomic Identification and Analysis
2D DIGE was performed by Applied Biomics (Hayward, CA); briefly: Following
protein extraction from tissue samples, proteins were covalently bonded to Cy2, Cy3, or
Cy5 dyes (GE Healthcare, Piscataway, NJ) and subjected to isoelectric focusing on a 3 10 immobilized pH gradient strip prior to analysis on a 9 - 13% gradient SDS-gel,
performed at 15° C until the dye front reached end of gel running plate. Image scans
were carried out immediately following the SDS-PAGE using Typhoon TRIO
(Amersham BioSciences, Piscataway, NJ). Scanned images were then analyzed by Image
Quant software (version 5.0, Amersham BioScience, Piscataway, NJ), and subjected to
in-gel analysis and cross-gel analysis using DeCyder software version 6.0 (Amersham
BioSciences, Piscataway, NJ). Selected spots were picked up by Ettan Spot Picker
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(Amersham BioSciences, Piscataway, NJ) following the DeCyder software analysis and
spot picking design. The selected protein spots were subjected to in-gel trypsin digestion,
peptide extraction, desalting, and then subjected to MALDI-TOF/TOF (Applied
Biosystems) analysis to determine protein identity. ProteinID scores >95% were
considered significant identifications.
Statistical Analysis
All experiments were arranged in a completely randomized block design and a
Kruskal-Wallis One Way Analysis of Variance on Ranks followed by Pairwise Multiple
Comparison (Student-Newman-Keuls Method) to calculate P-values (SyStat 2008) was
used to compare data. Differences with P-values < 0.05 were considered significant.
Results
Effect of ICPF on Serum levels of the Acute Phase Protein Serum Amyloid A
Stimulation of acute phase protein Serum Amyloid A (SAA) by ICPF, alone, and
with costimulation with S. typhimurium was evaluated in female Swiss Webster mice.
Naïve mice served as a negative control and a baseline with normal physiological
concentration of SAA of 1.05 ± 0.07μg/mL, correlating with established norms (Tape,
Tan et al. 1988; Lindhorst, Young et al. 1997). Within 6 hours of ICPF treatment, serum
concentration of SAA increased to 128 ± 51.7 μg/mL reaching 403 ± 80.9 μg/mL at 24
hours, and 3,480 ± 270 μg/mL at 48 hours (Figure 8). To serve as a positive control,
mice were injected ip with 1 x 103 CFU of S. typhimurium (Clarissa and Alexander 1999;
Hari-Dass, Shah et al. 2005). In this positive control, SAA values increased to 423 ±
30.3 μg/mL within 6 hours post exposure, peaked at 3,710 ± 95.8 μg/mL in 24 hours and
returned to 55 ± 14.8 μg/mL within 48 hours, slightly elevated, but not indicative of a
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typical acute phase response. Finally, we evaluated the response of SAA in animals
concurrently treated with ICPF and exposed to S. typhimurium. When mice where both
treated and challenged, a novel response by SAA was observed. Within 6 hours serum
concentration of SAA increased to 561 ± 100.0 μg/mL continued to increase to 1,331 ±
155.1 μg/mL at 24 hours and finally peaked at 1,671 ± 705 μg/mL, 48 hour post
treatment. Serum levels of SAA following ICPF stimulation indicate an increased acute
phase response when compared to the positive control at 48 hours (P < 0.05), as
determined by SAA concentration, however, a temporal shift of 24 hours results in a
delay for peak SAA concentration within the system when compared to positive control
(P < 0.05). During costimulation with ICPF and S. typhimurium, systemic levels of SAA
increased more rapidly than ICPF treated mice at 6 hours (P < 0.05) but no significant
differences were noted compared to S. typhimurium challenged mice (P > 0.05). SAA
concentrations in mice costimulated with ICPF and S. typhimurium were lower than mice
treated with ICPF alone (P < 0.05).
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Synergistic effects of ICPF and endotoxin stimulation on serum levels of
Serum Amyloid A.

ICPF, S. typhimurium, and combined ICPF and S. typhimurium on Serum Amyloid A
concentration in serum was determined using a sandwich ELISA in mice treated with 0.5
mg ICPF administered ip in 0.2 mL dPBS ∎, mice challenged ip with 5 x 103 CFU of S.
typhimurium ∎, and both ICPF and S. typhimurium ∎, ± S.E.M of n=5
2D DIGE Proteomic Identification and Analysis

Using 2D DIGE and DeCyder 6.0 image analysis software we investigated any
potential effects ICPF may have on systemic protein concentrations and post translational
modification on a systemic level. Following ip administration of 5 mg ICPF as
previously described, subjects were sacrificed and tissue samples analyzed by 2D DIGE.
For serum, respiratory, splenic, liver, and central nervous tissue, protein expression
profiles from a zero hour (control), 3 hour and 24 hour post treatment were determined, a
representative gel can be seen on (Figure 9). Several criteria were used to choose spots
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for possible MS/MS protein identification. A high degree of up/down regulation, at least
a 2 fold increase or decrease in intensity in order to select proteins with a greater
likelihood of being selectively modified. Intensity of spots, either weak or strong played
a role in identification likelihood, as weak proteins prove difficult to obtain a positive
mass spectrometry identification, while a strong spot indicates a higher probability of
being a structural protein or housekeeping enzyme by virtue of its high concentration
within the gel, so spots with medium intensity were chosen. Finally, whenever possible
we avoided known landmark protein locations, such as actin, tubulins, and heat shock
proteins, as they are not likely to play a significant role in the immunological reaction.
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A.

B.

Figure 9

C.

Representative 2D DIGE analysis.

A. 2D DIGE gel image of homogenized respiratory tissue at 0, 3 and 24 hours following
0.2 mL ip administration of 5.0 mg ICPF in SPF female Swiss Webster Mice. Proteins
were covalently bonded to Cy2, Cy3, or Cy5 dyes (GE Healthcare, Piscataway, NJ) and
subjected to isoelectric focusing on a 3 - 10 immobilized pH gradient strip prior to
analysis on a 9 - 13% gradient SDS gel. B. A detailed view of boxed region within 2D
DIGE image of homogenized liver tissue. C. 3-D fluorescence intensity profile of a
selected spot within the gel.
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Within central nervous tissue, 25 spots where chosen for protein identification by
MALDI-Mass Spectrometry. Of these 25 spots, 3 yielded possible secondary protein
identifications, resulting in 28 potential proteins which were differentially expressed or
underwent post translational modification(s) (Table 3). Respiratory tissue, consisting
predominantly of lung, yielded ten spots with an additional five secondary protein
identifications (Table 4). For serum, 20 spots were selected, based on the above
mentioned criteria for protein identification, however seven had weak mass spectrum
readings and conclusive protein identification was not possible, of the remaining 13
protein spots analyzed only six different proteins were identifiable (Table 5) with serum
albumin constituting the predominate duplicate/contaminating protein. Splenic tissue
yielded 15 unique differentially expressed proteins (Table 6) and hepatic (liver) tissue
(Table 7) yielded 21, 17 unique, differentially expressed proteins, of which ten have
specific enzymatic functions.
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Decreased

-3.3

3 Hour/Control
Abundance
Volume Ratio
Increased
2.49
Increased
2.06
Increased
2.02
Similar
-1.87
Increased
2.53
Decreased
-3.56
Increased
4.94
Decreased
-3.05
Similar
1.39
Decreased
-2.38
Increased
2.53
Increased
2.53
Increased
5.09
Increased
3.96
Similar
1.48
Similar
1.48
Increased
2.68
Decreased
-3.48
Increased
7.97
Increased
7.97
Decreased
-3.29
Similar
1.81
Similar
1.81
Increased
3.27
Increased
9.53
Similar
1.81
Similar
1.81
Decreased

-2.37

24 Hour/Control
Abundance
Volume Ratio
Similar
1.09
Similar
1.15
Similar
1.44
Similar
-1.63
Similar
1.13
Decreased
-2.67
Similar
1.05
Decreased
-3.6
Increased
2.16
Decreased
-2.31
Similar
-1.09
Similar
-1.09
Similar
-1.2
Similar
1.05
Similar
1.58
Similar
1.58
Similar
-1.02
Decreased
-2.98
Similar
-1.42
Similar
-1.42
Similar
-1.28
Similar
-1.01
Similar
-1.01
Similar
-1.33
Similar
-1.28
Similar
-1.15
Similar
-1.15
Similar

1.33

24 Hour/3 Hour
Abundance
Volume Ratio
Decreased
-2.41
Similar
-1.88
Similar
-1.47
Similar
1.09
Decreased
-2.36
Similar
1.27
Decreased
-4.96
Similar
-1.24
Similar
1.48
Similar
-1.02
Decreased
-2.89
Decreased
-2.89
Decreased
-6.43
Decreased
-3.94
Similar
1.02
Similar
1.02
Decreased
-2.87
Similar
1.11
Decreased
-11.84
Decreased
-11.84
Increased
2.45
Similar
-1.92
Similar
-1.92
Decreased
-4.55
Decreased
-14.34
Decreased
-2.45
Decreased
-2.45
Splice Isoform 2 of Syntaxin-binding protein 1

Most Likely Protein ID
Dnm1 protein [Mus musculus]
Transferrin [Mus musculus]
Low signal
Transferrin [Mus musculus]
BiP [Mus musculus]
Neurofilament-L
Protein disulfide-isomerase precursor
Dihydropyrimidinase-like 2 [Mus musculus]
Coronin, actin binding protein 1A [Mus musculus]
Pyruvate dehydrogenase E1 alpha 1 [Mus musculus]
Eef2 protein [Mus musculus]
Serpinb1a [Mus musculus]
Car6 protein [Mus musculus] (Carbonic anhydrase VI )
Interferon inducible protein 1 [Mus musculus]
G protein beta subuit like [Mus musculus]
Vacuolar ATP synthase subunit E (V-ATPase E subunit)
G protein beta subuit like [Mus musculus]
Quininoid dihydropteridine reductase [Mus musculus]
Phosphomannomutase 2 [Mus musculus]
Internexin neuronal intermediate filament protein, alpha
Peroxiredoxin-6
ES1 protein homolog, mitochondrial precursor
Peroxiredoxin-6
Superoxide dismutase [Mn], mitochondrial precursor
Glandular kallikrein K6 precursor
17 kDa protein (Peptidyl-prolyl cis-trans isomerase A)
Down syndrome cell adhesion molecule-like protein
IPI00415403

Accession
21961254
18606172
-18606172
2598562
200038
IPI00133522
40254595
31418362
13938051
38511951
56206897
29612611
6680351
475012
1718091
475012
12805283
28374408
34328368
IPI00555059
IPI00133284
IPI00555059
IPI00109109
IPI00323869
IPI00551246
IPI00408489

Differentially expressed central nervous tissue proteins identified by MALDI-TOF/TOF

Binding Protein

Functional Type
Cytoskeleton
Carrier
-Carrier
Chaperone
Cytoskeleton
Enzyme
Enzyme
Cytoskeleton
Enzyme
Elongation Factor
Protease Inhibitor
Enzyme
Chemokine
Second Messenger
ATPase
Second Messenger
Enzyme
Enzyme
Cytoskeleton
Enzyme
Mitochondrial
Enzyme
Enzyme
Serine Protease
Isomerase
Cellular Adhesion

Proteins which were either up or down regulated within central nervous tissue, accession numbers correlates to either NCBI
GenBank (Benson, Karsch-Mizrachi et al. 2005) or the International Protein Index (Kersey, Duarte et al. 2004) which is
denoted by an ‘IPI’ preceding the number. Spot numbers denoted with a prime signify situations where more than one likely
protein was identified, alternative protein ID listed in the subsequent row.
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Spot #
1
2
3
4
5
6
7
8
9
10
11
11'
12
13
16
16'
17
18
19
19'
20
21
21'
22
23
24
24'

Table 3

60

-1.98

Similar

Abundance
Increased
Similar
Similar
Similar
Similar
Similar
Similar
Similar
Similar
Similar
Similar
Similar
Similar
Similar
-1.41

Volume Ratio
6.03
-1.37
1.07
1.07
1.09
1.09
-1.17
-1.22
1.01
1.01
1.82
1.82
-1.28
-1.28
Similar

1.4

Volume Ratio
2.38
1.49
-1.54
-1.54
-1.82
-1.82
1.5
-2.11
1.49
1.49
1.39
1.39
1.57
1.57

24 Hour/3 Hour
Abundance
Increased
Similar
Similar
Similar
Similar
Similar
Similar
Decreased
Similar
Similar
Similar
Similar
Similar
Similar
Apolipoprotein A-I precursor [Mus musculus]

Most Likely Protein ID
NA (weak mass spectrum)
Albumin 1 [Mus musculus]
Dihydropyrimidinase-like 2 [Mus musculus]
EH domain containing protein [Mus musculus]
Electron transferring flavoprotein, dehydrogenase
Lamin A, isoform A [Mus musculus]
Pzp protein [Mus musculus]
Calponin 2 [Mus musculus]
Extracellular superoxide dismutase [Mus musculus]
Pzp protein [Mus musculus]
Carbonic anhydrase III [Mus musculus]
Aldh1a1 protein [Mus musculus]
1-Cys peroxiredoxin protein [Mus musculus]
Peroxiredoxin 6 [Mus musculus]
109571

Accession
-29612571
40254595
13938647
15214778
15929761
34785996
14318693
3320907
34785996
10717134
28386049
4139186
82892635
Carrier

Functional Type
-Carrier
Enzyme
Cytoskeleton
Enzyme
Kinase
Protease Inhibitor
Cytoskeleton
Enzyme
Protease Inhibitor
Enzyme
Enzyme
Enzyme
Enzyme

Proteins which were either up or down regulated within respiratory tissue, accession numbers correlates to either NCBI
GenBank (Benson, Karsch-Mizrachi et al. 2005) or the International Protein Index (Kersey, Duarte et al. 2004) which is
denoted by an ‘IPI’ preceding the number. Spot numbers denoted with a prime signify situations where more than one likely
protein was identified, alternative protein ID listed in the subsequent row.

Similar

10

Volume Ratio
2.55
-2.03
1.65
1.65
1.99
1.99
-1.75
1.73
-1.47
-1.47
1.31
1.31
-1.99
-1.99

24 Hour/Control

Differentially expressed respiratory tissue proteins identified by MALDI-TOF/TOF

3 Hour/Control

Abundance
Increased
Decreased
Similar
Similar
Similar
Similar
Similar
Similar
Similar
Similar
Similar
Similar
Similar
Similar

Spot #
1
2
3
3'
4
4'
5
6
7
7'
8
8'
9
9'

Table 4
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Abundance
Increased
Increased
Increased
Increased
Increased
Increased
Increased
Increased
Increased
Increased
Increased
Increased
Increased
Increased
Increased
Increased
Increased
Increased
Increased
Increased

3 Hour/Control
Abundance
Similar
Similar
Similar
Similar
Similar
Similar
Similar
Similar
Increased
Similar
Similar
Increased
Increased
Increased
Similar
Increased
Increased
Increased
Increased
Similar

24 Hour/Control
Abundance
Decreased
Decreased
Decreased
Decreased
Decreased
Decreased
Decreased
Decreased
Decreased
Decreased
Decreased
Decreased
Similar
Decreased
Decreased
Similar
Similar
Similar
Similar
Similar

24 Hour/3 Hour
Most Likely Protein ID
Transferrin [Mus musculus]
Serum Albumin (or its precursors or degradation product)
Serum Albumin (or its precursors or degradation product)
Serum Albumin (or its precursors or degradation product)
Serum Albumin (or its precursors or degradation product)
Serum Albumin (or its precursors or degradation product)
Keratin 18
NA (weak mass spectrum)
NA (weak mass spectrum)
NA (weak mass spectrum)
NA (weak mass spectrum)
NA (weak mass spectrum)
Immunoglobulin light chain variable region
Immunoglobulin light chain variable region
Serum Albumin (or its precursors or degradation product)
Serum Albumin (or its precursors or degradation product)
NA (weak mass spectrum)
Beta-2 Globin
Beta-1 Globin
NA (weak mass spectrum)

Differentially expressed serum proteins identified by MALDI-TOF/TOF.
Accession
18606172
20330098
20330098
20330098
20330098
20330098
254540068
-----5705888
5705888
20330098
20330098
-17647499
4760590
--

Functional Type
Carrier
Carrier
Carrier
Carrier
Carrier
Carrier
Cytoskeleton
-----Immunoglobulin
Immunoglobulin
Carrier
Carrier
-Immunoglobulin
Immunoglobulin
--

Proteins which were either up or down regulated within serum, accession numbers correlates to either NCBI GenBank
(Benson, Karsch-Mizrachi et al. 2005) or the International Protein Index (Kersey, Duarte et al. 2004) which is denoted by an
‘IPI’ preceding the number. Spot numbers denoted with a prime signify situations where more than one likely protein was
identified, alternative protein ID listed in the subsequent row.

Spot No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Table 5
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3 Hour/Control
Abundance
Volume Ratio
Increased
2.8
Similar
-1.83
Similar
1.42
Decreased
-3.76
Increased
2.63
Similar
1.79
Decreased
-10.5
Decreased
-3.4
Similar
1.98
Similar
1.84
Increased
2.58
Increased
2.24
Decreased
-3.56
Similar
-1.92
Decreased
-2.24

24 Hour/Control
Abundance
Volume Ratio
Increased
3.76
Similar
-1.9
Increased
2.01
Decreased
-3.69
Similar
-1.11
Similar
1.23
Decreased
-12.75
Decreased
-3.45
Similar
1.89
Similar
1.67
Similar
1.32
Increased
2.11
Similar
-1.31
Similar
-1.37
Similar
-1.5

24 Hour/3 Hour
Abundance
Volume Ratio
Similar
1.35
Similar
-1.04
Similar
1.42
Similar
1.02
Decreased
-2.91
Similar
-1.45
Similar
-1.21
Similar
-1.01
Similar
-1.04
Similar
-1.1
Similar
-1.95
Similar
-1.05
Increased
2.74
Similar
1.41
Similar
1.5

Most Likely Protein ID
Albumin 1
Placental protein 39
Methylenetetrahydrofolate dehydrogenase 1
Protein disulfide isomerase associated 2
Albumin 1
HNRPL
Hypothetical protein LOC67745
Zinc finger protein 647
Gamma actin
Gamma actin
Carbonic anhydrase 3
Car 1 protein
Peroxiredoxin 6
HNRPA 3
Glutathione S-transferase, Pi 1

Differentially expressed splenic tissue proteins identified by MALDI-TOF/TOF.
Accession
33859506
76639367
20270275
20899196
33859506
71119320
34304054
27370220
809561
809561
31982861
15029975
6671549
23274114
10092608

Functional Type
Carrier
Elongation Factor
Enzyme
Enzyme
Carrier
Ribonuclear
Unknown
DNA Binding Protein
Structural
Structural
Enzyme
Cytoskeletal
Enzyme
Ribonuclear
Enzyme

Proteins which were either up or down regulated within splenic tissue, accession numbers correlates to either NCBI GenBank
(Benson, Karsch-Mizrachi et al. 2005) or the International Protein Index (Kersey, Duarte et al. 2004) which is denoted by an
‘IPI’ preceding the number. Spot numbers denoted with a prime signify situations where more than one likely protein was
identified, alternative protein ID listed in the subsequent row.

Spot No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Table 6

63

Decreased

21

-2.73

-9.48
2.53
1.96
-1.48
1.14
2.12
2.08
-2.43
2.84
1.21
-1.67
-2.11
1.07
-3.41
1.69
-2.47
-8.54
3.53
-2.46
1.37

Volume Ratio

Decreased

-2.81

-14.31
5.54
2.43
-1.76
2.98
2.3
2.53
-2.81
2.79
4.07
-1.65
-2.33
3.74
-3.94
4.08
-2.14
-6.38
7.16
-1.07
3.45

Volume Ratio

24 Hour/Control
Abundance
Decreased
Increased
Increased
Similar
Increased
Increased
Increased
Decreased
Increased
Increased
Similar
Decreased
Increased
Decreased
Increased
Decreased
Decreased
Increased
Similar
Increased
Similar

-1.02

-1.49
2.22
1.26
-1.18
2.66
1.1
1.23
-1.14
-1
3.4
1.03
-1.09
3.55
-1.14
2.46
1.17
1.36
2.05
2.32
2.55

Volume Ratio

24 Hour/3 Hour
Abundance
Similar
Increased
Similar
Similar
Increased
Similar
Similar
Similar
Similar
Increased
Similar
Similar
Increased
Similar
Increased
Similar
Similar
Increased
Increased
Increased
Major Urinary protein 2

Most Likely Protein ID
Myosin heavy polypeptide 2
Carbamoyl phosphate synthetase 1
Carbamoyl phosphate synthetase 1
Leprecan-like 1 protein
Carbamoyl phosphate synthetase 1
Hypothetical protein XP_890111 isoform 1
Transferrin
Phosphoenolpyruvate carboxykinase 1
Aldehyde dehydrogenase 1
Heat Shock Protein 90, Grp94
Glutamate dehydrogenase 1
3-hydroxy-3-methylglutaryl-CoA synthetase 2
Immunoglobulin heavy chain variable region
4-hydroxyphenylpyruvate dioxygenase
S-adenosyl-L-homocysteine hydrolase
Leprecan-like 1 protein
Calreticulin
Carbonyl reductase
Indolethylamine N-methyltransferase
Carbonyl reductase
47059037

Accession
56206250
82879179
82879179
27527202
82879179
82942647
20330802
7110683
27532959
14714615
6680027
31560689
5705888
849053
904132
27527202
13097432
15215242
6678281
15215242

Enzyme

Functional Type
Structural
Enzyme
Enzyme
Unknown
Enzyme
Unknown
Carrier
Enzyme
Enzyme
Chaperone
Enzyme
Enzyme
Immunoglobulin
Enzyme
Enzyme
Unknown
Chaperone
Enzyme
Enzyme
Enzyme

Proteins which were either up or down regulated within hepatic tissue, accession numbers correlates to either NCBI
GenBank (Benson, Karsch-Mizrachi et al. 2005) or the International Protein Index (Kersey, Duarte et al. 2004) which is
denoted by an ‘IPI’ preceding the number. Spot numbers denoted with a prime signify situations where more than one likely
protein
was
identified,
alternative
protein
ID
listed
in
the
subsequent
row.

Abundance
Decreased
Increased
Similar
Similar
Similar
Increased
Increased
Decreased
Increased
Similar
Similar
Decreased
Similar
Decreased
Similar
Decreased
Decreased
Increased
Decreased
Similar

3 Hour/Control

Differentially expressed hepatic tissue proteins identified by MALDI-TOF/TOF.

Spot No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Table 7

Discussion
An immune response capable of reducing levels of a systemically infected
bacterium, such as the one initiated by ICPF would also be expected to alter protein
expression throughout several of an organism’s systems. Utilizing 2D DIGE our aim was
to (1) to verify that ICPF instigates a time-related proteomic shift and (2), identify
potential key proteins which, through their differential expression (as assessed by relative
abundance or post-translational modification) may help elucidate ICPF’s mode of action.
2D DIGE combined with MS/MS protein identification serves as a valuable tool for
biomarker identification of both diseased states and treatment efficiencies (Kondo 2008;
Poschmanna, Siteka et al. 2008).
We chose to investigate such changes within central nervous tissue as ICPF has
been implicated (unpublished) as a therapeutic agent for the treatment of symptoms
associated with multiple sclerosis, an autoimmune disease which results in
neurodegenerative demylenation of nerve cells. Cytokines, which are believed to play a
role in ICPF's mode of action are able to alter blood brain barrier characteristics and
integrity while triggering the release of additional downstream cytokines, prostaglandins,
nitric oxide, and other paracrine factors (Banks, Lynch et al. 2008) within central nervous
tissue. We used a subset of the total number of resolved proteins for identification and
several of the identified proteins show promise in having specific immune modulating
properties; particularly interferon inducible protein 1 (Irgm1) which showed a nearly
fourfold increase in expression within three hours of ICPF administration. Irgm1
expression is regulated by a type II interferon, IFN-γ, as well as the endotoxin
lipopolysaccharide (MacMicking, Taylor et al. 2003; Feng, Zheng et al. 2008) and has
been shown to be required for innate immune defense against several species of
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intracellular bacteria, including S. typhimurium (Shenoy, Kim et al. 2008). While little is
currently known about how Irgm1 is able to provide protection against such infections,
murine Irgm1 has been shown to increase autophagy and elimination of intracellular
bacteria within macrophages (Singh, Davis et al. 2006), and its presence and rapid up
regulation in the absence of lipopolysacharide implicate ICPF as either an inducer of
IFN-γ, a pluripotent innate immune cytokine or as a direct inducer if Irgm1. The later is
unlikely as there is no reason to suspect that ICPF would be able or does cross the blood
brain barrier, and IFN-γ shows little to no structural or sequence homology with ICPF.
Cytokines however, are typically transiently expressed (often in a series of wavelike
emanations) as low abundant proteins. The restoration of Irgm1 to a near baseline level
24 hours post-administration of ICPF may well mirror such an induced cytokine cascade.
In addition to interferon inducible protein, several proteins without direct or
apparent immunological functions have been identified within the brain as being up or
down regulated following ICPF administration. Five cytoskeletal related proteins where
found to be differentially expressed; dynamin like-1 protein which is believed to function
in microtubule transport of cellular vesicles and endocytosis (Leinonen, Nardone et al.
2006) was increased within three hours of treatment. Neurofilament-L and tropomyosin
β chain were decreased following treatment while α-internexin was increased before
subsequent down regulation at 24 hours. Neurofilament-L is a form of intermediate
filament which along with M and H forms, comprise neurofilaments (Shah, Flanagan et
al. 2000). Tropomyosin β chain binds actin filaments in association of with the troponin
complex (Brown, Kim et al. 2001) and α-internexin serves as an intermediate neural
filament which plays a role in cytoskeletal development and neuronal morphogenesis
(Liem and Messing 2009). Coronin-1A showed an increase at 24 hours following
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treatment and is believed to be a crucial component of the cytoskeleton of mobile cells
and is involved in cellular locomotion and phagosome fusion with lysosomes (Mugnier,
Nal et al. 2008). Several enzymes were differentially expressed within the brain
following ICPF treatment including; disulfide isomerase, carbonic anhydrase VI,
phosphomannomutase 2, and superoxide dismutase which were all up-regulated three
hours post treatment. Disulfide isomerase catalyzes the formation, breakage and
rearrangement of disulfide bonds (Darby, Freedman et al. 1994), carbonic anhydrase is
responsible for the reversible hydration of carbon dioxide, phosphomannomutase 2 is
involved in the synthesis of the GDP-mannose and dolichol-phosphate-mannose which is
required for a number of critical mannosyl transfer reactions (Mizugishi, Yamanaka et al.
1999; Leinonen, Nardone et al. 2006) and superoxide dismutase which destroys radicals
produced within the cells that are normally toxic to most biological systems. Enzymes
which were down regulated or expressed following ICPF treatment include
dihydropyrimidinase-like 2, pyruvate dehydrogenase, quinoid dihydropteridine reductase,
and peroxiredoxin-6. Dihydropyrimidinase roles include axon growth and guidance as
well as neural cell migration (Deo, Schmidt et al. 2004; Leinonen, Nardone et al. 2006)
while pyruvate dehydrogenase E1 α is a member of the pyruvate dehydrogenase complex
which catalyzes the conversion of pyruvate to acetyl-CoA and CO2 (Gopalakrishnan,
Rahmatullah et al. 1989; Leinonen, Nardone et al. 2006). Quinoid dihydropteridine
reductase produces tetrahydrobiopterin (BH-4) (Tegeder, Costigan et al. 2006), an
essential cofactor for phenylalanine, tyrosine, and tryptophan hydroxylases and
peroxiredoxin-6, a highly conserved thiol specific antioxidant protein (Eismann, Huber et
al. 2009). Additional proteins which showed an increase in expression within three hours
of treatment include; transferrin, a carrier protein responsible for iron sequestering and
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transport, a 70 kDa heat shock protein and chaperone found within the endoplasmic
reticulum, tubulin which is a major component of cellular microtubules, a G protein β
subunit which acts as an intracellular receptor to protein kinase C with potential kinase
activating properties (Leinonen, Nardone et al. 2006), and kallikrein, which is able to
selectively cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin
(Marcondes and Antunes 2005). Syntaxin-binding protein 1 expression was decreased
three hours following treatment and is thought to play a role in synaptic vesicle
endocytosis (Zanner, Gratzl et al. 2004; Leinonen, Nardone et al. 2006). Down syndrome
cell adhesion molecule-like protein expression was decreased at 24 hours and plays a role
in axon guidance, receptor regulation, targeting, and branching (Li and Guan 2004)
within drosophila, however its role in mice and humans is still unknown.
Liver and splenic tissue was evaluated due to ICPF's ability to reduce splenic
bacterial load in S. typhimurium infections (Willeford, Parker et al. 2001) and the liver’s
physiologic role in protein metabolism, acute phase protein regulation, and toxin
filtration. Within both splenic and hepatic tissue, no proteins of direct immunological
importance were identified. However, several metabolic enzymes such as
phosphoenolpyruvate carboxykinase, peroxiredoxin-6, methylenetetrahydrofolate
dehydrogenase 1, and aldehyde dehydrogenase (Table 7) and (Table 8), did show
significant alterations in expression levels, indicating possible modulation of metabolic
processes. Proteins which were decreased within the spleen following ip treatment with
ICPF include an uncharacterized disulfide isomerase, zinc finger protein 647 which is
thought to play a role in transcriptional regulation (Leinonen, Nardone et al. 2006),
peroxiredoxin-6 (previously described), and glutathione S-transferase which catalyses the
conjugation of reduced glutathione. Both carbonic anhydrase (previously described) and
67

methylenetetrahydrofolate dehydrogenase were increased following IPCF administration
within the spleen. Methylenetetrahydrofolate dehydrogenase roles include the catalysis
of the interconversion of tetrahydrofolate derivatives which are required for synthesis of
purines, thymidylate, and methionine (Tremblay, Mejia et al. 1992). Two heterogeneous
nuclear ribonucleo proteins (hnRNP A3 and hnRNP L) were identified within spleen
samples, however no changes in expression where noted. Within hepatic tissue, a myosin
associated peptide, phosphoenolpyruvate carboxykinase, 1,3-hydroxy-3-methylglutarylCoA synthetase, 4-hydroxyphenylpyruvate dioxygenase, leprecan-like 1 protein,
calreticulin, and indolethylamine N-methyltransferase were all down regulated within
three hours of ICPF administration. Phosphoenolpyruvate carboxykinase catalyzes the
conversation of oxaloacetate to phosphoenolpyruvate for the formation of glucose in
gluconeogenesis. 1,3-hydroxy-3-methylglutaryl-CoA synthetase condenses acetyl-CoA
with acetoacetyl-CoA to form HMG-CoA (Chang and Limanek 1980; Leinonen, Nardone
et al. 2006) and 4-hydroxyphenylpyruvate dioxygenase catalyzes the catabolism of
tyrosine (Leinonen, Nardone et al. 2006). Leprecan-like 1 protein (Prolyl 3-hydroxylase
2) catalyses the post-translational formation of 3-hydroxyproline in collagen types IV and
V (Mizuno, Hayashi et al. 2004; Leinonen, Nardone et al. 2006; Vranka, Pokidysheva et
al. 2010). Calreticulin is a calcium binding protein with chaperone properties commonly
found within the endoplasmic reticulum and indolethylamine N-methyltransferase
catalyzes the methylation of tryptamine (Leinonen, Nardone et al. 2006). Protein
expression which increased in hepatic tissue following ICPF treatment include carbamoyl
phosphate synthetase which is involved in ammonia removal via the urea cycle, 10formyltetrahydrofolate dehydrogenase which catalyzes the oxidation of 10formyltetrahydrofolate to CO2 and tetrahydrofolate (Schirch, Villar et al. 1994), heat
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shock protein 90, a stress induced chaperone, carbonyl reductase, an enzyme with a broad
substrate specificity able to catalyze the reduction of various carbonyl compounds
(Leinonen, Nardone et al. 2006). S-adenosyl-L-homocysteine hydrolase is believed to
play a role in the control of intracellular methylation reactions by regulating the
intracellular concentration of adenosylhomocysteine, which is a competitive inhibitor of
S-adenosyl-L-methionine-dependent methyl transferase reactions (Malanovic, Streith et
al. 2008).
Our serum profile was unable to detect any low abundant proteins (e.g. cytokines,
chemokines), possibly due to masking from several high abundant proteins such as serum
albumin, transferrin, and immunoglobulins, all of which were present at high
concentrations. Eighty five percent of serum protein composition (Echan, Tang et al.
2005) is composed of only six high abundant proteins, making the detection and
identification of differentially expressed low abundant proteins a challenging prospect.
Changes in protein concentrations within serum are carefully regulated by the body, and
often transient – compounding the experimental challenges in resolving them.
Respiratory tissue was evaluated due to ICPF's ability to alleviate lower
respiratory disease within horses (Hamm, Willeford et al. 2002) as well as the lungs
immunological role in early detection of inhaled pathogens (Murphy, Davis et al. 2004).
We attempted to identify 10 potential proteins which yielded differential expression
levels, however only three of the identified proteins, serum albumin,
dihydropyrimidinase-like 2, and Calponin 2 were differentially expressed with any level
of significance. Serum albumin represents the main protein of plasma and it serves as a
transfer protein with good binding capacities for water, Ca2+, Na+, K+, fatty acids,
hormones, bilirubin and drugs and in addition to analyte transport, it functions in the
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regulation of colloidal osmotic pressure of blood (Don and Kaysen 2004; Leinonen,
Nardone et al. 2006). Calponin 2 is a cytoskeletal protein which is believed to play a role
in the regulation and modulation of smooth muscle contraction, likely through its ability
to bind actin and calmodulin (Sugenoya, Yoshimura et al. 2002). Dihydropyrimidinaselike 2, an enzyme involved in nucleoside and nucleotide metabolism, was found to be up
regulated three hours following ICPF administration. The significance of this find relates
to previous work conducted in our lab which shows that ICPF is able to reduce
tumorgenesis by nearly 50% in murine respiratory melanoma (Parker, Willeford et al.
2005). While the precise role of dihydropyrimidinase-like 2 in the formation of lung
cancer remains questionable, it has been found to be down regulated in murine lung
adenocarcinoma models and up regulated in the presence of other immunotherapies
which have also been shown to be potent inhibitors of lung tumorigenesis (Bortner, Das
et al. 2009) however, another conflicting study, while also validating the down regulation
of dihydropyrimidinase-like 2 by carcinogens and in lung cancer, have yielded no
evidence of its upregulation in the presence of chemoprotective agents (Kassie, Anderson
et al. 2008). Five additional enzymes were identified in lung samples treated with ICPF;
however they showed no significant alterations in expression following treatment.
Electron transfer flavoprotein-ubiquinone oxidoreductase is a mitochondrial membrane
protein which is able to accept electrons from mitochondrial electron transfer
flavoprotein dehydrogenases and transport them to ubiquinone (Beckmann and Frerman
1985). Retinol dehydrogenase, a member of the aldehyde dehydrogenase family and its
roles include in the oxidation of aldehydes derived from biogenic amines such as
epinephrine and norepinephrine, as well as the aldehydes generated via lipid
peroxidation, and is often found in the liver, lung, and testis (Zhang, Chen et al. 2001;
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Maeda, Maeda et al. 2005; Leinonen, Nardone et al. 2006). Peroxiredoxin-6, carbonic
anhydrase, and superoxide dismutase (previously described) were also identified in lung
samples. Α-2 macroglobulin, a protease inhibitor (Armstrong and Quigley 1999) also
referred to as pregnancy zone protein, was identified. Two intracellular proteins, an
endosomal eps15-homology (EH) domain (Braun, Pinyol et al. 2005) and the structural
protein laminin A which are components of the nuclear lamina (Fong, Ng et al. 2006).
2D DIGE is a powerful tool in the search of differentially expressed proteins
which may play a role in pathogenesis or the therapeutic properties of a drug or immune
therapy, however it was not particularity well suited for the identification of small
peptides or low abundant proteins, especially in complex tissue system such as serum.
Removal of select high abundant proteins prior to 2D DIGE by either Cibricon Blue, a
chlorotriazine dye with a high affinity towards albumin (Gianazza and Arnaud 1982), as
well as immunoglobulin depletion matrixes Protein A and Protein G, where considered
but poor protein specificity and retention of low abundant proteins, which are often
nonspecifically bound to albumin, prevented its use. 2D DIGE also has limitations in its
resolving power, despite its impressive ability to resolve several hundred proteins on a
single gel, this number represents a fraction of the estimated 20,000 proteins expressed in
the mouse (Nekrutenko 2004).
In a more focused approach, systemic levels of the apolipoprotein Serum Amyloid
A was evaluated by ELISA. Acute phase proteins play a central role in innate immunity,
and SAA along with C-Reactive Protein are the major acute phase protein within
mammals, including man and has been used to screen for infectious diseases, to monitor
their response to therapy, and to distinguish between bacterial and viral infections
(Ducret, Bruun et al. 1996). SAA exists naturally within serum at low concentrations (171

5 μg/mL), usually complexed with high density lipoproteins, and during an acute phase
response may increase to nearly 1 mg/mL within 24 - 36 hours post stimulation (Clarissa
and Alexander 1999). SAA exists as 12kDa monomer, who's structure has not been fully
elucidated, in two isoforms, SAA1 and SAA2, however SAA1 is the predominant acute
phase form. During our analysis of SAA we were unable to differentiate between SAA1
and SAA2 due to considerable structural and sequence homology, they differ by 5 - 7
amino acids and both have 2 regions of high homology (Ducret, Bruun et al. 1996),
therefore we will use SAA to imply both isoforms, SAA1 and SAA2. ICPF's ability to
stimulate SAA expression shows for the first time a possible direct mode of action for
this peptides ability to alleviate mortality associated with gram negative induced sepsis.
SAA is capable of rapidly binding with great affinity to a common protein on the
membrane of gram negative bacteria, including S. typhimurium, known as Outer
Membrane Protein A (Hari-Dass, Shah et al. 2005) and act as an opsonizing agent by
assisting in phagocytosis for monocyte derived macrophages and neutrophils (Shah, HariDass et al. 2006). SAA is a type 1 acute phase protein produced largely by hepatocytes
initiated synergistically by Il-1 and Il-6 proinflamatory cytokines (Jiang, Lozanski et al.
1995). It is currently unknown if ICPF increase SAA concentration in vivo by direct
activation of hepatocytes or by triggering the synthesis and release of Il-1 and Il-6 from
an as yet unknown mechanism.
The upregulation of both Irgm1 and SAA and to a lesser extent,
dihydropyrimidinase-like 2, help advance our understanding of the immunotherapeutic
properties of ICPF within our model system. The opsonization and increased
phagocytosis induced by SAA in conjunction with possible increased elimination of
phagocytized intracellular bacteria from upregulation of the IFN-γ effector molecule,
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Irgm1 provides, for the first time, a detailed and working hypothesis for a mode of action
associated with ICPF's immune modulating properties for the sequestering and
elimination of S. typhimurium.
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CHAPTER IV
BIOASSAY DESIGN AND ANALYSIS OF CYTOKINE EXPRESSION IN VIVO AND
IN VITRO FOLLOWING ADMINISTRATIONS OF IMMUNE CELL
POTENTIATING FACTOR
Introduction
Cytokines and chemokines are key components in immune regulation and
activation, often thought of as the “hormones” of the immune system, they are typically
endogenous, extracellular immunoregulatory compounds. Cytokines are instrumental in
disease progression and diagnosis, as well as immune signaling with potential for both
autocrine and paracrine functionality. Both cytokines and chemokines are typically small
and proteinaceous, and their roles in the immune system, while often overlapping, may
differ considerably. Cytokines help regulate an immune response by signaling for a
particular cell type to increase in number (proliferation), differentiation, or maturation, as
in the case of lymphocytes and monocytes. The presence or absence of a particular
cytokine during an immunological challenge can alter the route of an infection as well as
the body’s reaction to a pathogen. Chemokines are typically responsible for bringing
different cell types together, operating in conjunction with specific receptors on both
myeloid and lymphoid cells, they work toward directing chemotaxis and generating a
localized immune response, as well as cellular activation, proliferation, and memory
(Murphy 2009). Both cytokines and chemokines typically work synergistically to
generate a myriad of immune responses, from an inflammatory event surrounding a
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wound, to systemic reactions such as; generating a fever, initiating an acute phase
response, or the activation of the complement cascade (Andrews, Feldhoff et al. 2003).
In recent years cytokines and chemokines have come to the forefront of
immunology as we have further elucidated their roles in disease and diagnosis. Many
autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus have
been shown to be caused, diagnosed, or successfully controlled (in some cases treated)
with cytokine and chemokine intervention therapies, such as etanercept, and adalimumab.
Both of which work by suppressing TNF-α (Lovell, Ruperto et al. 2008; Griffiths,
Strober et al. 2010) and anakinra, which is believed to act as an IL-1 receptor antagonist
(Botsios, Sfriso et al. 2007). Nearly every BRM currently on the market has a role as an
agonist or antagonist of cytokines or chemokines, additionally some BRM’s are nothing
more than recombinant cytokines, as is the case for IFN-α, IFN-γ and IL-2 (H Bönig, H-J
Laws et al. 2000; Stefania, Antonella et al. 2001) for the treatment of some cancers.
Our understanding of ICPF’s role in the inflammatory response, its reported
success in alleviating some of the symptoms of multiple sclerosis, as well as its apparent
potency in the murine sepsis model, may all be attributed to the regulatory control of
cytokines and chemokines. Cytokines and chemokines never work alone. One cytokine
can have several different effects on a system, sometimes starkly opposite effects.
Depending on the cell(s) that secreted the cytokine, the cell(s) the cytokine interact with,
and the location in the body of the previous dependencies, all play a role in the effect of
the immunological response, and ultimately on the organism. It is now also believed that
antibodies and other biological chemicals can interact with these cytokines to augment or
alter these effects, leading to yet another level of immunological regulation (Bradney,
Sempowski et al. 2002; Wassef and Plaeger 2002).
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Due to the pleotropic nature of most cytokines, the potential number of cells and
systems being affected by ICPF, and the possibility that ICPF may not be the only
component in the immune augmentation we have observed; delineating an accurate mode
of action for this compound has proven difficult. Through the use of single analyte
assays and systemic proteomic profiling by means of ELISA and 2D DIGE, we have
shown that ICPF can have a modulating effect on several proteins within the murine
model. However, a traditional ELISA is typically only able to measure a single cytokine
level within a sample at any given time and 2D DIGE, while capable of screening for
hundreds of potential proteins, has been inefficient at measuring specific, low abundant
proteins such as cytokines and chemokines in complex tissue samples. While knowing
the regulation of one cytokine can point us in a direction, it is imperative that we survey
several cytokine levels simultaneously within a single sample, as temporal variations
within different individuals, even within the same species, can vary dramatically.
Through the use of infrared (IR) multiplex protein arrays we can accurately measure the
levels of dozens of cytokines and chemokines at the same time within a single sample
from one individual, thereby elucidating complex cytokine pathways and a potential
mode of action.
In addition to elucidating ICPF’s mode of action, developing a new bioassay to
supplement our current animal mortality model was imperative. Further characterization
of ICPF as well as its immunological potentials has proven difficult due to the time, cost,
and ethical constraints involved in our animal mortality model. It was for these reasons
that we set out to develop an in vitro assay utilizing murine whole blood. A whole blood
assay capable of mirroring some of the in vivo biological responses to ICPF would allow
for greater flexibility for future testing and analysis of this and any subsequent
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derivatives/modifications of the peptide. Developing a new in vitro bioassay to study
mode of action was complicated due to our lack of understanding of the specific
biological changes induced by ICPF in vivo and we therefore chose to tackle both issues
concurrently by mapping any alterations in cytokine and chemokine expression by way of
a multiplex IR based Fluorescent Linked Immuno-Sorbent Assay (IR-FLISA).
Materials and Methods
Murine Animal Care and Maintenance
Specific Pathogen Free (SPF) female Swiss Webster mice were purchased from
Charles River Laboratories (Wilmington, MA). Mice were allowed to acclimate for 2
weeks upon arrival, during which time they were fed a standard maintenance diet
(Laboratory Rodent Diet 5001; PMI Feeds) and watered ad libitum. Mice were grouphoused (5 mice per cage) in plastic boxes bedded with wood shavings in an American
Association for the Accreditation of Laboratory Animal Care (AAALAC)-accredited
facility. The isolation room was maintained at 20° C in a controlled negative pressure
environment on a 12-h lighting cycle. Animal care and use were in accordance with the
policies of the Institutional Animal Care and Use Committee of Mississippi State
University protocol number 05-051.
Whole Blood Culture
Twenty five mL of EDTA heparinized murine whole blood (Bioreclamation,
Liverpool, NY) was diluted 1:5 (v/v) in RPMI 1640 (Thermo Scientific, Waltham, MA)
culture medium, distributed into 24-well tissue culture plates (1.5 mL/well) and
inoculated with 7.5 μl of 10 mg/mL ICPF (50 μg/mL) and serving as a negative control
7.5 μl sterile dPBS. Plates were incubated at 37° C with 5% CO2, cells and supernatant
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were collected at 0.5, 1.5, 3, 6, 12, 24, 48 and 72 hours, centrifuged at 900 RCF for five
minutes at 4° C and supernatant collected and frozen at -80° C until needed. Nucleated
cellular enumeration was determined utilizing a Nucleocounter™ from New Brunswick
Scientific (Edison, New Jersey) as per manufactures specifications.
Peripheral Blood Mononuclear Cell Preparation and Culture
Fifty mL of EDTA heparinized murine whole blood (Bioreclamation, Liverpool
NY) was centrifuged at 400 RCF for 10 minutes at 25° C. Buffy coat (thin white layer
between erythrocytes and serum) was collected and transferred to 14 mL conical tubes.
1:1 (v/v) of AKC erythrocyte lysis buffer (150 mM NH4Cl, 10 mM KHCO3, and 0.1 mM
EDTA•Na2) was added to buffy coat extract and gently agitated. Cellular suspension was
centrifuged at 400 RCF for 10 minutes at 25° C and supernatant discarded. The process
was repeated one additional time if needed. Remaining cells, predominantly leukocytes
and platelets were then diluted 1:5 (v/v) in RPMI 1640 culture medium, distributed into
24-well tissue culture plates (1.5 mL/well) and inoculated with 7.5 μl of 10 mg/mL ICPF
(50 μg/mL) and serving as a negative control, 7.5 μl sterile dPBS. Plates were incubated
at 37° C with 5% CO2. Cells and supernatant were collected at 0.5, 1.5, 3, 6, 12, 24, 48
and 72 hours, centrifuged at 900 RCF for five minutes at 4° C and supernatant collected
and frozen at -80° C until needed. Nucleated cellular enumeration was determined
utilizing a Nucleocounter™ from New Brunswick Scientific (Edison, New Jersey) as per
manufactures specifications.
Murine Serum Preparation and ICPF Administration
Sixty-nine mice were broken into two groups, a negative control and an ICPF
treated group. Mice within the treated group received a 0.2 mL ip inoculation of 5.0 mg
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ICPF in sterile dPBS. Negative control mice were sham handled and injected ip with 0.2
mL sterile dPBS. At 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 24 hours post treatment, three mice
from both groups (except 0 time point which consisted of only one group) were
anesthetized by CO2 asphyxiation and 0.8 – 1.0 mL blood collected by cardiac puncture,
mice were then humanely euthanized. Blood was placed in a 2 mL microtube and
allowed to clot for two hours at room temperature with gentle agitation. Samples were
then centrifuged at 1500 RCF for 10 minutes at 4° C and serum (30 – 40 μl) transferred to
a sterile tube and stored at -80° C until needed.
IL-6 IR-FLISA Development
Capture antibodies consisting of rat monoclonal anti-murine IL-6 (Abcam,
Cambridge MA) were diluted to 1.5 μg/mL and 100 μl added to each well of an optically
clear opaque walled 96-well fluorescence microplate (Thermo Scientific, Waltham, MA).
Capture antibodies were allowed to incubate overnight at 4° C with gentle agitation.
Non-bound capture antibodies were removed and wells washed 3 – 5 times with dPBS
and 0.05% Tween-20 to increase stringency of wash. 300 μl of blocking solution
consisting of either sterile 5% bovine serum albumin or 5% non-fat dried skim milk was
added to each well, and incubated at room temperature for 2 – 3 hours. Protein standards
consisting of recombinant murine IL-6 (Bender Medsystems, San Diego CA) were added
at 8.5 – 5,000 pg/mL in an 11 step 1:3 serial dilution, with one well serving as a blank.
Samples consisting of murine serum following ICPF administration at 0, 3, and 24 hours
(n = 3 per group) were diluted 1:1 in reagent diluent (0.1% BSA, 0.05% Tween-20,
0.02M Tris-Base, and 0.15 NaCl, pH 7.2), to reduce non-specific protein-protein
interactions and added to wells for eight hours at 4° C. Samples and standards were
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removed and wells washed as previously described. 100 μl rabbit anti-mouse IL-6
polyclonal antibody (Abcam, Cambridge, MA) was added to all wells at 8.5 μg/mL and
allowed to incubate for five hours at 4° C. Following an additional wash step, 100 μl of
goat anti-rabbit IR-680 antibody (Li-Cor Bioscience, Lincoln, Nebraska) was added. The
microtiter plate was scanned with an Odyssey™ Infrared Imaging System (Li-Cor
Bioscience, Lincoln, Nebraska) at 700 nm. IL-6 sample concentrations were determined
with Softmax Pro 4.6 (Molecular Devices, Silicon Valley, CA) software, using curve fit
models (log-log or 4-PL) as suggested by the manufacturer.
Multiplex Cytokine Analysis
The Pierce Endogen SearchLight™ Multiplex Protein Array (Pierce
Biotechnology, Rockford, IL), a 96 well plate based assay was utilized for the detection
of multiple cytokines and chemokine concentration determination. Calibration curves
were prepared in sample diluent, with a range of 5000 pg/mL to 0.4 pg/mL, dependent
upon the analyte being analyzed. Assay controls consisted of the sample diluent and the
corresponding calibration standard. The Pierce Searchlight Assay was essentially
performed as per the manufacturer’s instructions, briefly; 50 μl of cytokine/chemokine
standards and samples were loaded in duplicate (samples assayed in triplicate) to a 96
well microtiter plate, covered and allowed to incubate at 20 – 25° C for 3 hours on an
orbital shaker. Following the incubation period, the contents of the plate were discarded
and plate washed four times. 50 μl biotinylated antibody reagent was added to each well,
covered, and allowed to incubate for an additional 30 minutes. Contents were again
discarded and the plate washed four times. 50 μl of DyLight™800 (Pierce
Biotechnology, Rockford, IL) was added to each well and incubated for 30 minutes,
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discarded, and washed, as previously described. 300 μl ddH2O was added to each well,
and the plate centrifuged at 300 RFC for five minutes. The plate was then assayed using
an Odyssey™ Infrared Imaging System (Li-Cor Bioscience, Lincoln, Nebraska).
Instrumentation was set at a resolution of 84 μm, with a focus offset of 4 mm and
scanned at 800 nm. Sample cytokine concentrations were determined with Softmax Pro
4.6 (Molecular Devices, Silicon Valley, CA) software, using curve fit models (log-log or
4-PL) as suggested by the manufacturer (Figure 10) and (Table 8).
Statistical Analysis
All experiments were arranged in a completely randomized block design and a
Kruskal-Wallis One Way Analysis of Variance on Ranks followed by Pairwise Multiple
Comparison (Student-Newman-Keuls Method) to calculate P-values (SyStat 2008) was
used to compare data. Differences with P-values < 0.05 were considered significant.
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Figure 10

Representative scan and analysis of Searchlight™ Multiplex Protein Array

Four parameter logarithmic standard curve of IL-6 and representative IR-FLISA scan
with cytokine and chemokine designation overlay
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Table 8

Representative Multiplex FLISA Standard Curve

Rep 1

Rep 2

AVG

38236
12017
3643
1509
702
519
426
382

34137
11150
3610
1715
823
446
393
352

36186.4
11583.4
3626.4
1611.7
762.9
482.4
409.5
367

%C.V.
8
5.3
0.6
9
11.2
10.6
5.8
5.7

S.D.

pg/ml

BACKFIT

2898.4
613.7
23.4
145.8
85.5
51.3
23.6
20.9

2200
733.33
244.44
81.48
27.16
9.05
3.02
0

2258.7
746.1
229.4
91.4
30.5
9.2
3.4
1

a
b
c
d
R2
LOD (pg/ml)
LOQ (pg/ml)

370.31
1.05
39541026
1.01E+09
0.9923
3.33
10.01

Representative Curve Fit Analysis and coefficient of determination and intra assay
coefficient of variance.
Results
IL-6 in vitro IR-FLISA Development
A single analyte in vitro IR-FLISA was developed to detect IL-6 in both
Peripheral Blood Mononuclear Cells (PBMC) as well as whole blood to determine any
effect ICPF had over cytokine expression and as a ‘proof of concept’ before multiplex
protein array technology would be considered. Initial IL-6 levels were at or below the
assays detectable limits of 5.5 pg/mL. Following administration of 7.5 μl of 10 mg/mL
ICPF (50 μg/mL), IL-6 concentration increased to 113 ± 28.1 pg/mL within three hours
(P < 0.05) and returned to an in vitro physiological baseline (≤5.5 pg/mL) (P < 0.05)
within 24 hours post exposure (Figure 11a). An intra assay coefficient of variance was
calculated to be <25%. SDS-PAGE and fluorescent western blot analysis was conducted
on samples and standards to determine the presence of any potential non-specific or
antibody cross-reactivity which would compromise FLISA results (Figure 11b) and
antibody binding appeared limited to IL-6. Cellular enumeration was determined to be
1.83 x 106 live nucleated cells per well for isolated PBMC.
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Figure 11

IR-FLISA development

A. Murine PBMC in a 24 well culture plate were treated with 50 μg/mL ICPF. Nontreated cells served as a zero time point and baseline for IL-6 expression. At 3 and 24
hours post ICPF treatment, cells were removed, centrifuged and supernatant assayed for
IL-6 expression. IL-6 concentration was determined in pg/mL ± S.E.M of n=3.
Significant differences between ICPF treated samples and controls (P < 0.05) are noted
with an asterisk. B. IR-Fluorescent western blot analysis of IL-6 standards with
detection and signal antibodies utilized in IR-FLISA.
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In vivo Multiplex Cytokine Analysis
SPF Swiss Webster mice cytokine profiles were evaluated using Pierce
Searchlight Multiplex protein array technology. Cytokine expressions evaluated
following 5 mg ip ICPF injection included IL-1α, IL-1β, IL-2, Il-4, Il-5, IL-6, KC
(CXCL1), IL-10, IL-12p40, IL-13, IFN-γ, and TNF-α with dPBS serving as a negative
control. IL-6 concentrations increased to 611±22.1 pg/mL (P < 0.05) within one hour of
ICPF treatment. Within two to three hours, IL-6 levels began dropping, reaching
136±8.5 (P < 0.05) and 44.8±8.7 pg/mL (P < 0.05) respectively. Within four hours IL-6
had returned to a concentration not significantly different than physiological baseline (P >
0.05) and remained at these levels for the duration of the study (Figure 12a). IFN-γ
concentration increased to 197 ±65.0 pg/mL (P < 0.05) within one hour post treatment
and returned to a concentration not significantly different than physiological baseline (P >
0.05) within two hours (Figure 12b). Slight fluctuations within IFN-γ continued for the
duration of the study, however they remained low and were determined to not be
significantly different from negative control.
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In vivo cytokine expression following ICPF treatment

A. IL-6 expression in vivo following ip administration of 5 mg ICPF. Three mice from
each time point received ip 0.2 mL dPBS serving as a negative control, while three
additional mice from each time point were treated ip with 5 mg ICPF. IL-6 concentration
was determined in pg/mL ± S.E.M of n=3 with an average intra assay coefficient of
variance of 7.0%. Significant differences between ICPF treated mice and controls (P <
0.05) are noted with an asterisk. B. Expression of IFN-γ within previously described
mice. IFN-γ concentration was determined in pg/mL ± S.E.M of n=3 with an average
intra assay coefficient of variance of 7.25%. Significant differences between ICPF
treated mice and controls (P < 0.05) are noted with an asterisk.
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The only murine chemokine to show any significant increase over the negative
control following ICPF treatment was KC, also known as CXCL1. KC is a murine
chemokine belonging to the CXC family of mouse chemokines. Following ICPF
administration, KC increased in concentration to 61.3±3.3 pg/mL (P < 0.05) from a
physiological baseline of 2.5 pg/mL, KC continued to increase in the blood for an
additional hour; peaking at 104.7 ± 6.4 pg/mL (P < 0.05) at two hours post injection
before beginning to decrease to 40.2 ± 7.6 pg/mL (P < 0.05) and beginning at three hours
and within four hours KC had returned to physiological base line. At seven hour post
treatment, the systemic concentration briefly increased to 40.46±13.0 pg/mL (P < 0.05)
before once again returning to baseline which was determined to not be significantly
different from negative control (P > 0.05) (Figure 12).
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Figure 13

In vivo chemokine expression following ICPF treatment

KC expression in vivo following ip administration of 5 mg ICPF. Three mice from each
time point received ip 0.2 mL dPBS serving as a negative control, while three additional
mice from each time point were treated ip with 5 mg ICPF. KC concentration was
determined in pg/mL ± S.E.M of n=3 with an average intra assay coefficient of variance
of 8.5%. Significant differences between ICPF treated mice and controls (P < 0.05) are
noted with an asterisk.
In vitro Multiplex Cytokine Analysis
In vitro cytokine analysis was performed on whole blood in order to both confirm
results documented within in vivo studies as well as aid in future bioassay design. IL-6
and IFN-γ were both expressed in similar patterns as seen in vivo, with IL-6 expression
peaking at 385±24.3 pg/mL (P < 0.05) at three hours before returning to baseline which
was determined to not be significantly different from negative control (P > 0.05). IFN-γ
expression increased slightly earlier to 77.8±7.9, pg/mL (P < 0.05) within 1.5 hours of
treatment with ICPF and remained elevated at 54.0±4.3, pg/mL (P < 0.05) at three hours
post treatment (Figure 14). The ratio of IFN-γ to IL-6 expression showed similar trends
between in vivo and in vitro studies, with IFN-γ expression being approximately 30% of
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IL-6 in the live mouse and 20% in tissue culture. In addition, the temporal relationship
between the two cytokine expression profiles, with IFN-γ preceding IL-6 indicates a
potential causal relationship. There were however, no significant changes noted within
the CXCL1 chemokine expression in vitro (P > 0.05). Cellular enumeration was
determined to be 5.89 x 106 live nucleated cells per well for this whole blood culture.
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IL-6 and IFN-γ expression in vitro following ICPF treatment of murine
whole blood

A. IL-6 expression in vitro following treatment of 50 μg/mL ICPF in whole blood and B.
IFN-γ expression in vitro following treatment of 50 μg/mL ICPF in whole blood. IL-6
and IFN-γ concentration was determined in pg/mL ± S.E.M of n=3 with an average intra
assay coefficient of variance of <15%. Significant differences between ICPF treated
samples and controls (P < 0.05) are noted with an asterisk.
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Discussion
Septicemia is a highly complex and poorly defined condition that results from a
systemic inflammatory response, usually the result of endotoxemia caused by a systemic
infection from a gram-negative bacteria and the body’s natural attempt at eradicating the
pathogen. Following a successful immunological response to such an infection, typically
catalyzed by the administration of antibiotics, dead and dying bacteria release large
quantities of endotoxin, usually in the form of lipopolysaccharides (LPS). Circulating
LPS is quickly bound by LPS-Binding Protein (LBP) which forms an immune complex
recognized by TLR-4 and complement receptors of the innate immune system that trigger
the release of proinflammatory cytokines (Li and Verma 2002; Li, Holers et al. 2002;
Nautiyal, McKellar et al. 2009) such as IL-1, IL-6, TNF-α, and the murine chemokine
KC (Osuchowski, Welch et al. 2006; Peyssonnaux, Cejudo-Martin et al. 2007). It is
believed that an over expression of these proinflammatory cytokines, possibly
compounded with inadequate expression of anti-inflammatory cytokines, all contribute as
the primary causative agent of sepsis and septic shock. Due to this mechanistic
understanding, many attempts have been made to utilize anti-inflammatory cytokines and
antibodies directed at proinflammatory cytokines to preemptively target this underlining
cause of sepsis. Despite several successful animal trials (Zeni, Freeman et al. 1997;
Nasraway 1999) none, save IFN-γ for the treatment of injury induced sepsis (Polk Jr,
Cheadle et al. 1992), have proven successful in human clinical phase II or III trials
(Nasraway 2003) and some have concluded with disastrous results, leading to potential
cytokine storms and increased mortality (Fisher, Agosti et al. 1996).
While ICPF has been shown to induce the expression of proinflammatory
cytokines (Figure 15) while reducing mortality in a bacterial induced sepsis model
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(Figure 5) the effect on endotoxemic (LPS) induced sepsis (Figure 3) was dismal.
Recently another theory attempting to explain sepsis has been gaining momentum, which
challenges the notion that an initial overproduction of proinflammatory cytokines is the
primary causative agent in the susceptibility to septic shock (Netea, van der Meer et al.
2003). This theory proposes that an initial deficiency in proinflammatory cytokine
expression and production allows for rapid proliferation and systemic spread of the
invading bacteria, resulting in higher levels of endotoxin release following the
corresponding immune response, resulting in systemic inflammatory response syndrome
(SIRS) and compensatory anti-inflammatory response syndrome (CARS), which can lead
to multisystem organ failure, shock, and ultimately death (Netea, van der Meer et al.
2003).

92

700.000

Concentration, pg/mL

600.000
500.000
400.000
300.000
200.000
100.000
0.000
1

2

3

Time, hours

Figure 15

Expression of proinflammatory cytokines following administration of ICPF

∎ IL-6, ∎ IFN-γ, and ∎ KC in vivo expression following ip administration of 5 mg ICPF.
Three mice from each time point received ip 0.2 mL dPBS serving as a negative control
(data not shown), while three additional mice from each time point was treated ip with 5
mg ICPF. Cytokine concentration was determined in pg/mL ± S.E.M of n=3 with an
average intra assay coefficient of variance of 7.0%.
The rapid expression of IL-6, IFN-γ, and CXCL1 (KC) by ICPF may be
alleviating septicemia induced mortality by priming the innate immune system and
allowing for an increased immune response to the invading pathogen, preventing
systemic bacterial dissemination, endotoxemia, and ultimately septic shock. While ICPF
has been known to reduce systemic levels of S. typhimurium within two days of treatment
and infection (Willeford, Parker et al. 2001), no mechanism for this activity has
previously been proposed.
Critical to further study and analysis of ICPF is the development of a reliable and
cost effective bioassay to serve as an alternative to the current murine animal model. In
addition to analyzing cytokine expression in vivo, cytokine values were determined in
vitro following ICPF treatment. It was our hope that the cytokine expression profiles
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would match that seen within the organism, as we wanted the indicator to be a function of
ICPF and its immune effect. While CXCL1 was not identified as an up regulated
chemokine in vitro, both IFN-γ and IL-6 were up regulated within three hours of
treatment, at nearly the same time as in vivo. We believe that the combined temporal
proximity and relative expression levels of IL-6 and IFN-γ in vivo and in vitro, in
response to administration of ICPF to be an excellent indicator of potential immune
function, and further speculate that a whole blood cellular assay which mimics, at least in
part, the prophylactic properties induced by ICPF is now in preliminary testing. Before
such a bioassay can be validated, it remains to be seen if the same mechanism inducing
these early proinflammatory cytokine expressions in vivo is taking place in vitro which
future work hopes to address.
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CHAPTER V
CONCLUSION
IL-6, while being a highly pleiotropic cytokine with both pro and antiinflammatory properties, has been shown to be instrumental for early activation of both B
and T lymphocytes (Van Snick 1990) and hepatic induction of type 1 and 2 acute phase
proteins, such as C-reactive protein and Serum Amyloid A (SAA), both of which serve a
protective role as innate immune opsonins for S. typhimurium and other gram negative
bacteria (Szalai, VanCott et al. 2000; Hari-Dass, Shah et al. 2005; Shah, Hari-Dass et al.
2006). The increased expression of IL-6 by ICPF is able to explain for the first time the
systemic increase in SAA previously observed (Figure 8). IFN-γ plays an essential role
in the activation of macrophages and successful clearance of phagocytized intracellular
pathogens such as S. typhimurium. Upon phagocytosis of certain intracellular bacteria,
macrophages release IL-12 which induce IFN-γ production by NK and T-cells (Stark
2007). The IL-12 subunit, IL-12p40 was also shown to be up regulated (data not shown)
by ICPF in vitro however we were unable to detect its expression in vivo, possibly due to
its temporal expression and our selection of chosen time points or insufficient systemic
levels being expressed. IFN-γ is essential to the activation of interferon inducible protein
1 (Irgm1) which was also found to be up regulated by ICPF. IFN-γ and Irgm1 are both
important to a successful immune response towards S. typhimurium, as intracellular
bacteria have evolved several specific strategies to avoid host defense and clearance once
phagocytized by a macrophage, such as preventing IFN-γ mediated macrophage
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maturation and possibly Irgm1 induced phagosome clearance (Donné, Pasmans et al.
2005; Henry, Daniell et al. 2007). We contend that induction of IFN-γ by ICPF, either
directly or by activation of macrophages, possibly via a TLR, is able to activate Irgm1,
thereby allowing for increased intracellular bacterial clearance.
CXCL1/keratinocyte-derived chemokine (KC) is one of only four murine CXC
chemokines containing the Glycine-Leucine-Arginine (ELR) motif, despite the
identification of seven such chemokines within humans (Lin, Carlson et al. 2007).
CXCL1 also serves as a murine homolog of the human oncogene termed GRO (Growth
Regulated Oncogene), is mainly induced by LPS in macrophages and vascular cells and
is associated with neutrophil recruitment and inflammation (Rubio and Sanz-Rodriguez
2007). ELR+/- chemokines, such as CXCL1 and CCL2 have been shown to precede
proinflammatory cytokine and innate inflammatory responses within six hours of
infection and impedance of this early chemokine response can result in more aggressive
bacterial infection, proliferation, and possibly increased mortality (van der Zee, Dik et al.
2010).
Osuchowski, Welch et al. (2006) provides an excellent analysis of both pro and
anti-inflammatory cytokine profiles following experimentally induced sepsis by cecal
ligation and puncture in mice. While their observed increase in total serum concentration
of these cytokines was considerably higher (1,000 fold) than what we observed following
ICPF administration their results are otherwise very similar to our own in respect to
proinflammatory cytokines.
Osuchowski, Welch et al. observed a significant increase in IL-6 and CXCL1 in
mice which succumbed to sepsis within 1-5 days post challenge yet these
proinflammatory mediators were not noted in mice which survived or took longer to
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succumb, suggesting a temporal relationship between the correlation of increased IL-6
and CXCL1, and mortality attributed to sepsis. In addition to the increased levels of IL-6
and CXCL1 as compared to ICPF, their earliest reported point of measurement was six
hours post challenge, while we observed an increase in IL-6 and CXCL1 within 1-4
hours, and a return to baseline by six hours (Figures 12 and 13). While excessive levels
of IL-6 in the range of 10 μg/mL have been shown to jeopardize host defense against a
bacterial infection (Soda, Kano et al. 2003), our highest concentration of IL-6 (611±22.1
pg/mL) were well below those shown to increase mortality. Osuchowski’s analysis of
proinflammatory cytokines prior to sepsis did not include IFN-γ; deficiences in IFN-γ
expression have been reported to be associated with increased susceptibility to infections
and potential sepsis (Borges, Augustine et al. 2000; Netea, van der Meer et al. 2003;
Takeyama, Tanaka et al. 2004) and its administraion has been used successfully to treat
sepsis following severe injury (Polk Jr, Cheadle et al. 1992).
The prophylactic properties generated by ICPF in response to S. typhimurium
induced sepsis are propagated through a rapid stimulation of the innate immune response,
via stimulation and expression of proinflammatory mediators. Specifically IL-6, IFN-γ,
and CXCL1 and the rapid elimination of the causative agent S. typhimurium, partially
through activation and increased expression of Irgm1 and SAA before systemic levels of
bacteria and endotoxins are able to overwhelm the body’s ability to compensate (Figure
16). This theory is further supported by the inability of ICPF to protect mice directly
challenged with S. typhimurium derived lipopolysaccharides, as the induction of
proinflammatory cytokines would be of little help, and possibly detrimental to
survivability during such a challenge.
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Diagram of proposed mechanism for ICPF prophylactic treatment of S. typhimurium

A. Sepsis model where low proinflammatory cytokine expression immediately following an infection results in poor activation of
innate immune systems, deficient elimination of bacterial infection, and exponential systemic bacterial growth. When the innate
immune system is able to mount an effective response to the infection, the increased bacterial load would result in a massive
proinflammatory response resulting in Systemic Inflammatory Response Syndrome (SIRS) followed by death or
Compensatory/Mixed Anti-inflammatory Response Syndrome (CARS/MARS), staling of the immune response, possibly resulting
in death. B. Proposed mode of action for ICPF following S. typhimurium infection. IL-6, IFN-γ, and CXCL1 (KC) expression as

Figure 16
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determined by multiplex FLISA analysis, Serum Amyloid A expression as determined
by ELISA, and interferon inducible protein 1 determined by 2D DIGE. We propose that
an early increase in proinflammatory cytokines and chemokines, specifically IL-6, IFN-γ,
and CXCL1, combined with an prolonged acute phase response with Serum Amyloid A
(SAA), and augmented macrophage intracellular bacterial clearance from increased
expression of interferon inducible protein 1 (Irgm1) stemming from prophylactic
administration of ICPF, allows an organism to more fully respond to an initial bacterial
challenge, preventing systemic bacterial growth and proliferation, and ultimately
preventing sepsis induced death rium derived sepsis
Continued research pertaining to ICPF’s mode of action should concentrate on the
importance of the up-regulated cytokines and chemokines following ICPF administration,
either by utilizing cytokine deficient mice (developed through selective breeding
programs or via molecular knockout) or by coupling ICPF with neutralizing antibodies
directed against select proinflammatory cytokines. Utilizing in vivo protein profiles,
while ideal, presents several limitations in terms of costs and practicality associated with
the use of live animal models. To address these restrictions, single or mixed cell cultures
should be evaluated and if possible, developed to further advance our understanding of
the cells responsible for these early cytokines. The development of a mono-culture able
to respond to ICPF in a manner which mirrors an in vivo response will also be essential to
determine the pharmacokinetics and specific receptors involved with ICPF.
Discovering agents that potentiate the immune response is a driving force in
modern bio-rational drug research (Taylor and Wright 2008) and our ability to analyze
immunological, biochemical, and molecular pathways have led to significant discoveries
in this field over the last three decades. While there are many potential pathways, both
immunological and pathogenic to potentially exploit, the number of successful and safe
therapies remain low (Chan 2008). General immune stimulants and cytokine factors such
as interferons, interleukins, and inflammatory antagonists currently in use, although
potentially providing dramatic therapeutic results, require dosages at concentrations that
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often produce toxic side effects which make them intolerable to many patients and have
thus not proven good candidates for wide-spread, general use (Kruth 1998; Nasraway
2003). The need to augment our antimicrobial arsenal is driven not just by the desire to
increase human welfare, but by the increasing threat of antimicrobial resistant pathogens
in both human medicine and food animal production (Liu, Huang et al. 2008; Silbergeld,
Graham et al. 2008). Currently, the majority of antibiotics in use today were discovered
over 50 years ago and methacillin-resistant Staphylococcus aureus, vancomycin-resistant
enterococci, and multidrug resistant gram negative bacteria, such as Salmonella enteritis
have become an increasingly serious problem for human welfare (Taylor and Wright
2008).
Despite the considerable questions which remain surrounding ICPF’s mode of
action, ICPF has proven to safely provide a significant health benefit when administered
prophylactically. ICPF can be provided prophylactically or administered therapeutically
without interfering with other therapeutic modalities such as those requiring antibiotic or
antiviral regimes (Figure 6). The typical “ICPF dose” (0.25 mg/g) has not promoted a
recorded harmful side effect. ICPF did not affect cell viability or inhibit protein
translation as assessed in canine diploid fibroblasts (Figure 7) or cause the hemolysis of
red blood cells when the culture mediums were supplemented with up to 1 mg/ml ICPF
(Table 2). Animals previously subjected to ten times the therapeutic dosage did not
demonstrate toxicity nor experience a “Delayed Type Hypersensitivity Reaction” when
re-exposed (data not shown) and PulmoClear ™, which constitutes a crude formulation of
ICPF, is a USDA approved product for equine lower respiratory disease. World-wide,
infectious disease and sepsis remain a leading cause of mortality. It seems promising that
if further researched and developed, ICPF could augment our therapeutic arsenal.
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